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Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the National Board of Occupational
Safety and Health (NBOSH). In most cases a scientific basis is written on request from
the NBOSH. The Criteria Group shall not propose a numerical occupational exposure
limit value but, as far as possible, give a dose-response/dose-effect relationship and the
critical effect of occupational exposure.
In searching of the literature several data bases are used, such as RTECS, Toxline,
Medline, Cancerlit, Nioshtic and Riskline. Also information in existing criteria
documents is used, e.g. documents from WHO, EU, US NIOSH, the Dutch Expert
Committee for Occupational Standards (DECOS) and the Nordic Expert Group. In some
cases criteria documents are produced within the Criteria Group, often in collaboration
with DECOS or US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariate or by a scientist appointed
by the secretariate. A qualified evaluation is made of the information in the references. In
some cases the information can be omitted if some criteria are not fulfilled. In some cases
such information is included in the report but with a comment why the data are not
included in the evaluation. After discussion in the Criteria Group the drafts are approved
and accepted as a consensus report from the group. They are sent to NBOSH.
This is the 18th volume which is published and it contains consensus reports approved
by the Criteria Group during the period July 1996 to June 1997. Previously published
consensus reports are listed in the Appendix (p 73).
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1Consensus Report for Diethylene Glycol Ethyl
Ether and Diethylene Glycol Ethyl Ether
Acetate
December 11, 1996
Chemical and physical characteristics. Uses. (11, 16, 44)
Diethylene glycol ethyl ether (DEGEE)
CAS No: 111-90-0
Synonyms: 2-(2-ethoxyethoxy)ethanol, ethoxy diglycol, carbitol, 
diethylene glycol monoethyl ether, diglycol ethyl ether,
beta-ethoxy-beta’-hydroxy diethyl ether, ethyl carbitol
Formula: CH3CH2–O–CH2CH2–O–CH2CH2–OH
Molecular weight: 134.2
Density: 0.99 (20 ° C)
Boiling point: 202 ° C
Melting point: - 76 ° C
Vapor pressure: 19 Pa (0.14 mm Hg) (25 ° C)
Relative evaporation rate: 0.02 (n-butyl acetate = 1)
Saturation concentration: 180 ppm (25 ° C)
Conversion factors: 1 ppm = 5.58 mg/m3 (20 ° C)
1 mg/m3 = 0.179 ppm (20 ° C)
Diethylene glycol ethyl ether acetate (DEGEEA)
CAS No: 112-15-2
Synonyms: 2-(2-ethoxyethoxy)ethyl acetate, ethyl diglycol acetate,
diethylene glycol monoethyl ether acetate,
carbitol acetate, ethyl carbitol acetate
Formula: CH3CH2–O–CH2CH2–O–CH2CH2–O–C=OCH3
Molecular weight: 176.2
Density: 1.01 (25 ° C)
Boiling point: 217 ° C
Melting point: - 25 ° C
Vapor pressure: 7 Pa (0.05 mm Hg) (20 ° C)
Relative evaporation rate: ‹ 0.01 (n-butyl acetate = 1)
Conversion factors: 1 ppm = 7.32 mg/m3 (20 ° C)
1 mg/m3 = 0.137 ppm (20 ° C)
2At room temperature, diethylene glycol ethyl ether (DEGEE) and its acetate ester
(DEGEEA) are colorless liquids with faint, sweet, pleasant odor and bitter taste. Their
boiling points are relatively high and vapor pressures and evaporation rates low. Like most
glycol ethers, both substances have very good solubility and mix completely with water
and with both polar and non-polar solvents. The reported odor thresholds are 1.2 mg/m3
(0.21 ppm) for DEGEE and 0.18 mg/m3 (0.025 ppm) for the acetate ester (41). Another
source (21) gives ‹ 0.21 ppm as the absolute odor threshold for DEGEE and 1.1 ppm as
the recognition threshold.
In 1993 DEGEE was registered as an ingredient in 178 Swedish chemical products, and
estimated annual use was just under 500 tons of pure substance. The major area of use was
as solvent, but the substance was also used in paint, varnish, cleaners and binders. In
Sweden DEGEE is not used in pharmaceuticals or non-prescription diet supplements, but
does occur in cosmetics and skin care products (personal communication, Cecilia Ulleryd,
Swedish Medical Products Agency, Nov. 15, 1996). In the United States, DEGEE was
reported to occur in 80 cosmetic preparations in 1981 (1). The substance, under the name
Transcutol®, is used in skin medications (33) and it has also been found in chemical air
fresheners for consumer use (5).
The use of DEGEE in Sweden increased rapidly from 1985 to 1992, and in the following
year as well (26, 27). DEGEE, along with mono-(EGBE) and diethylene glycol butyl ether
(DEGBE), have been identified as the solvents most widely used in water-based paints and
varnishes (22). Global use in 1993 was estimated to be 31,000 tons (13).
Air levels up to 4 mg/m3 DEGEE have been measured around indoor painting with
water-based paints (personal monitors, 20 monitoring occasions) (38). Air levels of 0.2
mg/m3 have been reported after application of ”safe varnish” (schadstoffarmen
Dispersionslacken) containing 0.2% to 0.3% DEGEE (31). DEGEE has frequently been
identified in polluted groundwater in the United States (40).
In one study (28), 2-(2-ethoxyethoxy)acetic acid was identified in the urine of about 20
patients. The authors concluded that the substance was formed by biotransformation of
DEGEE or its derivatives, but were unable to show any connection to specific
pharmaceuticals or other environmental exposures.
DEGEEA occurred in 48 Swedish products in 1993; total use was 900 tons/year, mostly
in paints and varnishes (27).
Uptake, biotransformation, excretion
Toxic effects, excretion of metabolites in urine, and comparisons with related glycol ethers
all indicate that DEGEE and DEGEEA are efficiently absorbed via all paths of uptake. A
man given a single oral dose of DEGEE (11.2 mmol) excreted 68% of the dose as 2-(2-
ethoxyethoxy)acetic acid in urine within 12 hours (28). There is no other quantitative
information on uptake.
Uptake of DEGEE by prepared human epidermis was 0.125 mg/cm2/hour (10), slower
than glycol ethers with shorter chains, such as diethylene glycol methyl ether (DEGME),
3and faster than those with longer chains, such as DEGBE. DEGEE has been used to
accelerate dermal absorption of medications (see e.g. Reference 33).
No systematic studies of the distribution of DEGEE or DEGEEA in the body have been
published. The very low octanol-water coefficient (log POW = - 0.15) of DEGEE (34)
implies that the substance is probably distributed in body fluids rather than accumulated in
fatty tissue.
Esters of glycol ethers are efficiently hydrolyzed by the carboxylesterase in body tissues.
In rat blood, for example, the acetate ester DEGBEA is broken down to DEGBE with a half
time of less than 3 minutes (8). It can be assumed that DEGEEA is similarly transformed to
DEGEE.
The primary metabolic pathway should be analogous to that of other glycol ethers:
oxidation of the hydroxyl group in DEGEE via aldehyde to carboxylic acid, i.e. 2-(2-
ethoxyethoxy)acetic acid (24). Similarly, the other major metabolic pathway would involve
splitting of the central ether bond to ethylene glycol ethyl ether and subsequent oxidation to
2-ethoxyacetic acid (24). Support for the existence of these metabolic pathways is provided
by the human study mentioned above (28) and indirectly by a study with pregnant mice that
were given diethylene glycol dimethyl ether by gavage (7).
Dogs given DEGEE (3 to 5 g/kg) orally or subcutaneously excreted much higher




DEGEE has moderate acute toxicity. The LD50 for oral doses of DEGEE is 5.4 to 7.9 g/kg
for rats (2, 32), 7.9 g/kg for mice (2), 3.9 g/kg for guinea pigs (32), and 3.6 g/kg (50% in
water) for rabbits (45). With intraperitoneal injection, the LD50 is 3.9 to 5.2 g/kg for mice
(2, 29). With dermal application, the LD50 is 6.0 g/kg for rats and 8.4 g/kg for rabbits (18).
In a 90-day study, rats were given 0%, 0.5%, 1% or 5% DEGEE in food. Effects were
observed only in the highest dose group: one death (1 male of 12 males and 12 females),
reduced food intake, lower weight gain, swollen testes, hydropic degeneration of the liver,
and kidney effects in the form of higher relative weight, hydropic degeneration, proteinuria
(males only) and elevated aspartate aminotransferase (ASAT, GOT) activity in urine. The
NOEL (No Observed Effect Level) was reported to be 1% DEGEE (17).
In another 90-day study, DEGEE was given in food to rats and mice (10 – 20 of each
sex per dose group) and by gavage to pigs (3 of each sex per dose group). Effects noted in
the highest dose groups (rats 5%, mice 5.4%, pigs 1000-1500 mg/kg/day) were deaths (no
rats), reduced food intake, lower weight gain, reduced blood hemoglobin, oxaluria (rats
and mice only), and effects on kidneys (lower relative weights, degeneration and atrophy
of proximal renal tubuli, calcification of renal cortex) and liver (hydropic degeneration,
periportal fatty degeneration, enlarged liver cells) (not rats). Effects on kidneys and liver
were also observed in the next-highest dose groups (mice 1.8%, pigs 500 mg/kg/day). The
NOEL was reported to be 0.5% (equivalent to about 250 mg/kg/day) for rats, 0.6% (850-
41000 mg/kg/day) for mice, and 167 mg/kg/day for pigs. No effects were seen on serum
levels of urea or aminotransferases (ASAT and ALAT) in any dose group. The results
indicate that pigs are most sensitive and rats least sensitive of the three species studied (14).
 The same or similar effects were also observed in older studies in which DEGEE was
given to rats and mice in food or drinking water (19, 30, 36).
In an eye irritation test with rabbits, made in accordance with OECD guidelines, DEGEE
was classified as non-irritating to eyes (23). In an older study of eye irritation, also made
with rabbits, DEGEE and its acetate were reported to be slightly irritating to eyes (2 on a
10-point scale), as were, for example, DEGME and its acetate (4). DEGEE has been used
as a model substance in at least ten studies of in vitro alternatives to the eye irritation test
(see for example Reference 15). In all these studies, the observed effects of DEGEE were
slight.
No information was found on lethal levels for inhalation exposure. Considering the
saturation concentration and the oral LD50 values, lethal air levels can hardly occur under
normal conditions. Histological examination of rats and guinea pigs exposed for 8 hours to
air saturated with DEGEEA at room temperature revealed lung and kidney damage (Union
Carbide, unpublished data, 1939, cited in Reference16). In a teratogenicity study with rats,
no maternal toxicity was observed after exposure to 100 ppm DEGEE 7 hours/day for 9
days, but the report contains no further details (37).
Human data
There are no reports on effects of occupational exposure.
There is one case report describing a man who drank about 300 ml of DEGEE. He
developed severe symptoms of poisoning: CNS effects, breathing difficulty, thirst,
acidosis and albuminuria (3).
An unpublished report (Kligman, 1972) cited by Opdyke (39) describes dermal
application of 20% DEGEE in petroleum jelly, under occlusion, to 25 volunteers for 48
hours. The application resulted in no irritation or sensitization. In another sensitization
study, pure DEGEE was applied under occlusion to the backs of 98 young men for 7 days,
followed by a 3-day application 10 days later. No skin sensitization or edema was
observed, but 7 of the men had prounounced skin reddening (6).
Mutagenicity, carcinogenicity
DEGEE was weakly mutagenic in bacterial tests, non-mutagenic to yeast, and non-
mutagenic in a micronuclei test with bone marrow from mice (2). There are no mutagenicity
studies of DEGEEA. With only a few exceptions, glycol ethers have been found to be non-
mutagenic in several different mutagenicity tests (35).
No cancer studies of DEGEE or DEGEEA were found. In an older experiment that was
not designed to study cancer, 10 rats were exposed to a bit over 2% DEGEE in food for
two years. No observations of tumors were reported (36), though the thoroughness of the
histopathological examination is not clear.
5Addition of DEGEE (0.01 – 2 mM) caused a dose-dependent inhibition of cell
proliferation in vitro in cultures of several types of cells, including human fibroblast,
lymphoma and mastocytoma cells. The inhibition was not accompanied by cytotoxic effects
(33).
Two months of treatment with DEGEE (2.5 or 5 g/l in drinking water) had no effect on
the leukemia response in male rats. In this respect it differs from both ethylene glycol
methyl ether, which eliminated all indications of leukemia after injection of leukemia cells,
and ethylene glycol ethyl ether, which dramatically reduced them (9).
Reproduction toxicity
In a screening test, female mice were given DEGEE by gavage (5.5 g/kg/day) on days 7 to
14 of gestation. Despite pronounced maternal toxicity (7 of 50 died; 0 in controls), only
slight effects were observed in young: reduced birth weight, but no reduction in survival or
growth (43).
In a teratogenicity study, 19 female rats were exposed to 102 ppm DEGEE 7 hours/day
on days 7 to 15 of gestation. The authors report that this was the highest possible exposure
level, since higher levels resulted in aerosol formation. No effects were observed in young.
The factors studied were food intake and growth of the mothers, litter size, numbers of
implants, resorptions and living pups, their birth weights, and any deformities or anomalies
in bones or tissues. The authors also mention that no maternal toxicity was observed, but
do not report what variables were checked (37).
In another teratogenicity study, 13 rats were given dermal applications of DEGEE four
times per day (6.6 g/kg/day) on days 7 to 16 of gestation. The mothers showed a slight
effect in the form of lower weight gain, and there were skeletal aberrations in their young
(missing, extra or fused ribs etc.), but no increase in the number of skeletal or visceral
deformities (20).
In a pilot study made to determine the suitability of the fruit fly (Drosophila
melanogaster) for teratogenicity screening, a tendency to a higher number of anomalies was
observed after treatment with DEGEE. There were not enough flies studied to allow a
proper statistical analysis, however (42).
In a multi-generation study (continuous breeding protocol), mice were given up to 2.5%
DEGEE in drinking water (equivalent to about 4.4 g/kg/day). There were no observed
effects on either their reproductive ability or that of their young. In the highest dose group,
however, males had reduced sperm motility and females elevated liver weights; their young
also had lower birth weights (46).
A small portion of DEGEE is very probably broken down to the toxic metabolite
ethoxyacetic acid. This might explain the toxic effects on reproduction observed after high
doses of DEGEE. The related substance ethylene glycol monoethyl ether, which is
metabolized largely to ethoxyacetic acid, has toxic effects on reproduction at much lower
doses (see e.g. Reference 25).
6Dose-effect / dose-response relationships
Table 1. Dose-effect relationships observed in laboratory animals given DEGEE.
______________________________________________________________________________________
Species         Dose








6.6 dermal, days 7-16
of gestation
Lower weight gain, skeletal variations in
young, no increase in number of
deformities
20
2.7 - 5.5 5% in food, 90
days
Deaths, lower food intake and weight gain,
reduced blood Hb, swolllen testes, effects
on liver and kidneys, oxaluria
14, 17
? 1% in food, 90
days
No observed effects 17
0.26 - 0.57 0.5% in food, 90
days
No observed effects 14
Mouse 7.9 Single oral dose LD50 2
7.0 - 12.9 5.4% in food, 90
days
Deaths, lower food intake and weight gain,
reduced blood Hb, effects on liver and
kidneys, oxaluria
14
5.5 Oral, days 7-14 of
gestation
7 of 50 females died, pups had lower birth
weights
43
4.4 2.5% in drinking
water (continuous
breeding protocol)
Reduced sperm motility (males), elevated
liver weights (females), pups with lower
birth weights, no effects on reproductive
ability
46
2.5 - 4.6 1.8% in food, 90
days
Effects on liver and kidneys 14
0.8 - 1.1 0.6% in food,  90
days
No observed effects 14
Pig 1.5 Oral, daily for 90
days
Deaths (3 of 6), experiment aborted, severe
anemia
14
1.0 Oral, daily for 90
days
Lower food intake and weight gain, reduced
blood Hb, effects on liver and kidneys
14
0.5 Oral, daily for 90
days
Effects on liver and kidneys 14
0.17 Oral, daily for 90
days
No observed effects 14
________________________________________________________________________
7The only published inhalation study reports no observed effects after exposure to 100 ppm
DEGEE 7 hours/day for 9 days. There are no other data on which to base a dose-effect or
dose-response relationship for inhalation exposure. The dose-effect relationships for oral
and dermal administration to mice, rats and pigs are summarized in Table 1.
Conclusions
There are no data on human exposures from which a critical effect of diethylene glycol
ethyl ether (DEGEE) or its acetate ester (DEGEEA) can be determined. Judging from
animal experiments, the critical effect is damage to kidneys and liver.
Effects on kidneys and liver are observed at relatively high doses (about half the lethal
doses), and effects on testes and sperm at somewhat higher doses. There are also
indications of effects on young, in the form of lower birth weights and skeletal variations.
There is no information on effects of occupational exposure to either substance, and there
are virtually no toxicological data for DEGEEA. Analogies drawn from other glycol ethers
make it reasonable to assume that DEGEEA is rapidly transformed to DEGEE in the body
and that the two substances thus have the same toxicity.
DEGEE is absorbed via skin. It is reasonable to assume that both substances, like other
glycol ethers, are efficiently absorbed via both skin and inhalation.
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Consensus Report for Ethene
December 11, 1996
Physical and chemical data. Occurrence
CAS No: 74-85-1
Systematic name: ethylene
Synonyms: acetene, elayl, olefiant gas
Formula: CH2=CH2
Molecular weight: 28.05
Density: 0.98 (air = 1)
Boiling point: - 104 ° C
Vapor pressure: 4270 kPa (0 ° C)
Melting point: - 169 ° C
Explosion threshold: 2.75 vol % in air (100 kPa; 20 ° C)
Distribution coefficient: log POW = 1.13 (octanol/water)
Conversion factors: 1 ppm = 1.15 mg/m3
1 mg/m3 = 0.87 ppm
Ethene at room temperature is a colorless gas with a sweet odor and taste. The reported
odor threshold is 290 ppm (333.5 mg/m3) (1, 26). The gas dissolves readily in water,
acetone, ethanol and benzene. Ethene is stable under normal pressure and temperature
conditions, but may polymerize at higher pressure and temperature.
Ethene is used primarily in the production of polyethylene and ethylene oxide / ethylene
glycol. It is also used as a raw material in the production of other chemical substances.
Ethene is used to accelerate the ripening of fruit. (It is formed naturally by ripening fruit.)
There are virtually no data on occupational exposure to ethene in connection with
production of the substance. It is usually produced in closed systems. In one study (17) it
is estimated that during the years 1941 to 1947 the exposure level for ethene around
production of ethylene oxide was about 600 mg/m3. Measurements of occupational
exposure to ethene in warehouses where the gas is used to control the ripening of bananas
showed air concentrations ranging from 0.02 to 3.85 mg/m3, with a mean value of 0.35
mg/m3 (28). In a study of firemen, it was found that they were exposed to ethene in some
phases of fighting fires (20).
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Uptake, biotransformation, excretion
Six volunteers were exposed to 0, 5 or 50 ppm ethene (0, 5.75 or 57.5 mg/m3) for two
hours. Most (94.4%) of the inhaled ethene was immediately exhaled. Calculations based on
clearance of uptake and metabolic clearance indicated that alveolar retention at steady state
was 2% and the biological half time was 0.65 hours (12). From theoretical calculations of
gas uptake in the lungs, it can be concluded that the low uptake of ethene is due to its low
solubility in blood.
Ethene can be detected in exhaled air of unexposed persons. Women exhale more ethene
at the time of ovulation. The biochemical origin of this endogenously produced ethene has
not been explained, but four theories have been proposed: lipid peroxidation, enzyme-
catalyzed oxidative breakdown of methionine, oxidation of hemoglobin, and metabolism in
intestinal bacteria (18).
Two hemoglobin adducts, N-(2-hydroxyethyl)histidine (HOEtHis) and N-(2-
hydroxyethyl)valine (HOEtVal), have been used as dose measures for formation of
ethylene oxide from ethene.
Exposure to ethene at concentrations of 10 to 20 ppb (11.5 to 23 m g/m3) has been
associated with an increase of adducts (HOEtVal) amounting to 4 – 8 pmol/g Hb at steady
state (29). Fruit store workers exposed to 0.02 to 3.35 ppm ethene (0.023 to 3.85 mg/m3)
had adduct (HOEtVal) levels of 22 to 65 pmol/g Hb; levels in unexposed controls were 12
to 27 pmol/g Hb (28). The adduct level due to endogenous ethylene alone is estimated to be
about 12 pmol/g Hb (12).
It has been estimated from adduct data that about 2 to 3% of inhaled ethene is
metabolized to ethylene oxide (14, 28). Exposure to 1 ppm ethene (1.15 mg/m3) for 40
hours/week is calculated to increase the adduct level by 100 to 120 pmol/g Hb (9).
Mice were exposed to 17 ppm (22.3 mg/m3) 14C-labeled ethene for one hour. Four hours
later radioactivity was found primarily in kidneys and liver, with lesser amounts in testes
and brain. A 48-hour urine sample contained S-(2-hydroxyethyl)cysteine, indicating that
the ethene had been metabolized to ethylene oxide (8). Fischer-344 rats that were exposed
to 10,000 ppm (11,500 mg/m3) radioactively labeled ethene for 5 hours eliminated most of
the radioactivity as exhaled ethene, while smaller amounts were excreted in urine and feces
or exhaled as CO2. Minor amounts of radioactivity were found in blood, liver, intestines
and kidneys. The amounts of radioactivity in urine and CO2 were higher in animals that had
been pre-treated with Aroclor (a commercial PCB mixture), which indicates that ethene
metabolism can be stimulated by substances that induce the mixed function oxidase system
(15).
When Sprague-Dawley rats were exposed to between 0.1 and 80 ppm (0.12 and 92
mg/m3) ethene, they eliminated 24% of available ethene by biotransformation and 76% by
exhalation of unchanged ethene. The alveolar retention at steady state was 3.5% and the
biological half time was 4.7 minutes (12). Metabolism was saturated at concentrations
above 80 ppm (92 mg/m3), with a maximum metabolism rate (Vmax) of 0.24 mg/hour x kg
body weight (11).
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When Sprague-Dawley rats were exposed for 21 hours to ethene levels exceeding 1000
ppm (1150 mg/m3) the amount of ethene absorbed per unit of time was constant (2). When
Fischer-344 rats were exposed to 600 ppm (690 mg/m3) ethene, the blood level of ethylene
oxide rose rapidly during the first five to ten minutes and then dropped to a level that
remained constant during the remainder of the 60-minute exposure.  The level of
cytochrome P-450 in liver declined steadily during the experiment (22). This was taken to
indicate that during metabolism of ethene the phenobarbital-induced form of cytochrome P-
450 is destroyed by transformation of the cytochrome heme to an abnormal porphyrin (23).
Sprague-Dawley rats were exposed to 300 ppm (345 mg/m3) ethene 12 hours/day for
three consecutive days: the concentration of ethene was low in all examined organs 12
hours after the last exposure. However, the levels of hemoglobin adducts and of 7-
alkylguanine in lymphocytes and liver were elevated, indicating the formation of ethylene
oxide (10).
Hemoglobin adduct (HOEtVal) levels of about 100 pmol/g Hb have been measured in
several strains of rats, mice and hamsters after exposure to ethene (18). Calculations based
on animal data indicate that uptake of 1 mg ethene per kg body weight corresponds to a
tissue dose of ethylene oxide amounting to 0.03 mg x hour/kg body weight. This value
agrees with the one calculated for human uptake (32).
Toxic effects
Ethene is not irritating to eyes or skin (4). People exposed to a concentration of 37.5% in
air for 15 minutes experienced some memory disturbance, and 50% in air results in loss of
consciousness due to oxygen deprivation (4).
Mice repeatedly exposed to concentrations resulting in loss of consciousness showed no
histopathological changes in kidneys, adrenal glands, heart or lungs (24). The
concentration was described as ”atmosphere in which the partial pressure of oxygen was 20
per cent and ethylene 90 per cent.”
Fischer-344 rats exposed to 10,000 ppm (11,500 mg/m3) ethene for 5 hours showed no
toxic effects (15). Nor were toxic effects observed in Sprague-Dawley rats with ethene
exposures up to 10,000 ppm (11,500 mg/m3) 6 hours/day, 5 days/week in a 90-day study
(25), or in Fischer-344 rats with exposures up to 3000 ppm (3450 mg/m3) in a two-year
study (16). This absence of toxicity may be due to saturation of ethene metabolism (18).
Rats pre-treated with Aroclor and 24 hours later exposed to ethene concentrations of
10,000, 30,000 or 57,000 ppm (11,500, 34,500 or 65,550 mg/m3) for 4 hours had dose-
dependent effects on liver, indicated by elevated serum levels of sorbitol dehydrogenase
and alanin-a -ketoglutarate transaminase and by the histological observation of centrilobular
necrosis (5, 6, 15).
Mutagenicity, carcinogenicity, teratogenicity
Ethene caused no mutations in tests with Salmonella typhimurium (TA 100), either with or
without metabolic activation (34). Ethene induced no micronuclei in the bone marrow of
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rats and mice exposed to up to 3000 ppm (3450 mg/m3) 6 hours/day, 5 days/week for four
weeks (33).
The DNA adduct 7-(2-hydroxyethyl)guanine (7-HOEtGua) was found in levels of 2 to 6
nmol/g DNA in lymphocytes from untreated Sprague-Dawley rats (13) and in DNA from
several different tissues from Fischer-344 rats and B6C3F1 mice (35). After mice were
exposed for eight hours to 11 ppm (12.9 mg/m3) radioactively labeled ethene, 7-alkylation
of guanine could be demonstrated in DNA from liver, spleen and testes: 0.17 nmol/g DNA
was measured in liver; 0.098 in spleen and 0.068 nmol/g DNA in testes, which was less
that 10% above the background level (27).
Groups of Fischer-344 rats (120 of each sex) were exposed to 0, 300, 1000 or 3000
ppm (0, 345, 1150 or 3450 mg/m3) ethene 6 hours/day, 5 days/week for up to 24 months.
Rats were sacrificed and examined after 6, 12, 18 and 24 months. There was no difference
in survival between exposed rats and controls. Histological comparisons of the high-dose
group and the controls revealed no indications of any exposure-related toxicity and no
elevated incidence of tumors (16).
Groups of Sprague-Dawley rats (both sexes) were exposed to 0 or 10,000 ppm ethene (0
or 11,500 mg/m3) 8 hours/day, 5 days/week for three weeks. One week later the animals
were given polychlorinated biphenyls (unspecified), 10 mg/kg body weight, by gavage
twice a week for 8 weeks. The animals were then sacrificed and examined for ”ATPase-
deficient foci.” There was no difference between the ethene-exposed animals and controls.
(When ethylene oxide was used as a positive control, there was a pronounced increase of
foci.) (7)
According to the IARC (18), it is not possible to determine whether ethene is
carcinogenic to either man or experimental animals (”inadequate evidence”) and ethene has
therefore been placed in Group 3: ”unclassifiable as to its carcinogenicity to humans.” As
for the metabolite ethylene oxide, in the judgement of the IARC (19) there is ”limited
evidence” that it is carcinogenic to humans and ”sufficient evidence” that it is carcinogenic
to experimental animals, and in the overall assessment ethylene oxide is therefore placed in
Group 1: ”carcinogenic to humans.”
In a theoretical presentation (29, 30, 31) it is postulated that ethene might cause cancer
via activation to ethylene oxide which then binds to DNA, and that the consequent risk of
cancer in Sweden due to ethene in city air would be equivalent to 30 cases per year (at an
average exposure of 1.8 mg/m3).
One study reports 6 miscarriages among 15 pregnant women who were working in a
petrochemical industry. This rate was higher than that for 1,549 women who were living in
the surrounding area. The main product was ethene (350,000 tons/year), but the women
were also exposed to other substances including ethylene oxide, vinyl chloride and
phthalates. No exposure data are given, but measured ethene concentrations in air outside
the plant were on average 10 to 15 ppb (2).
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Dose-response / dose-effect relationships
There are no data that can be used as a basis for calculating a dose-effect or dose-response
relationship for human exposure to ethene. Occupational exposures of 0.023 to 3.5 mg/m3
have resulted in elevated formation of hemoglobin adducts (28). Data from animal studies
are summarized in Table 1.
Table 1. Effects of ethene inhalation on experimental animals.
________________________________________________________________________
mg/m3 Duration Species   Effects Ref.
________________________________________________________________________
    12.9 8 hours Mouse   7-alkylation of guanine in DNA 27
       92 6 hours Rat   Saturation of ethene metabolism 11
   3450 28 days Mouse   No increase in micronuclei 33
   3450 2 years Rat   No toxic effects 16
11,500 5 hours Rat   No toxic effects 15
11,500 90 days Rat   No toxic effects 25




Judging from available data on toxicity to humans, the critical effect of exposure to ethene
is its effect on the central nervous system. (Ethene has been used as an anesthetic.) From
animal data it can be observed that, if the animals have been enzyme-induced, effects on the
liver may be the critical ones.
It has been debated whether exposure to ethene can give rise to toxic effects and/or
cancer caused by the metabolite ethylene oxide. In its 1981 report, the Criteria Group stated
that the critical effects of exposure to ethylene oxide were the mutagenic, cytogenetic and
carcinogenic effects, and that cytogenetic effects of ethylene oxide were seen at
occupational exposures of about 2 mg/m3 (21).
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Consensus Report for Cyanoacrylates
March 5, 1997
This report is based mostly on a criteria document from the Nordic Expert Group for
Criteria Documentation of Health Risks from Chemicals (46) and covers primarily methyl
2-cyanoacrylate and ethyl 2-cyanoacrylate.
Chemical and physical data. Uses.
Methyl 2-cyanoacrylate (46)
CAS No: 137-05-3
Synonyms/trade names: mecrylate, 2-propenoic acid, 2-cyano methyl ester,  
methyl 2-cyano-2-propenoate, 2-cyanoacrylic acid 
methyl ester, methyl a -cyanoacrylate
Formula: C5H5NO2
Molecular weight: 111.10
Vapor pressure: 0.33 kPa at 48 ° C (11)
‹ 0.27 kPa at 25 ° C (14)
0.026 kPa at 10 ° C (73)
Conversion factors: 1 ppm = 4.53 mg/m3
1 mg/m3 = 0.22 ppm
Methyl 2-cyanoacrylate at room temperature is a thin, colorless liquid with a sharp odor.
The odor threshold is between 1 and 5 ppm. The substance is soluble or partially soluble in
methyl ethyl ketone, toluene, N,N-dimethylformamide, acetone and nitromethane.
Ethyl 2-cyanoacrylate (46)
CAS No: 7085-85-0
Synonyms/trade names: ethyl cyanoacrylate, ethyl 2-cyano-2-propenoate,
2-propenoic acid 2-cyano ethyl ester
Formula: C6H7NO2
Molecular weight: 125.12
Vapor pressure: ‹ 0.27 kPa at 25 ° C (14)
Conversion factors: 1 ppm = 5.12 mg/m3
1 mg/m3 = 0.20 ppm
Ethyl 2-cyanoacrylate at room temperature is a clear, colorless liquid with an irritating odor.
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Cyanoacrylates have the following general chemical structure:
           C = N alkyl 2-cyanoacrylate
| monomer
  H2C3 = C2
|
          
1COOR
where R = - CH3 gives methyl 2-cyanoacrylate, R = - CH2- CH3 gives ethyl 2-
cyanoacrylate, etc.
Adhesives based on alkyl 2-cyanoacrylate were introduced on the market in the late
1950s. The bonding ability of cyanoacrylates is believed to be the result of an anion
polymerization that is exothermic and rapid – within minutes or seconds, even at room
temperature. Heat, extreme pressure, or addition of solvents or special catalysts are not
necessary, since the polymerization is initiated by weak bases such as water and alcohols,
or nucleophilic groups of proteins such as amines or hydroxyl groups, which are on the
surfaces to be joined. Because of their ability to form strong bonds with a large number of
materials – rubber, metals, glass, wood, plastic, leather, cork, nylon, ceramics, porcelain
etc. – they were soon widely used in a variety of industries. The methyl and ethyl
derivatives were particularly popular, and were later marketed for household use (14, 18).
For practical reasons it is often desirable to alter their physical characteristics, and glue
formulations intended for commercial use may therefore contain a number of different
additives (14).
Some cyanoacrylates, particularly the n-butyl and isobutyl derivatives, have also been
tested and used as surgical adhesives. Their advantages are that they are biologically
degradable and that they can polymerize on damp surfaces, which makes it possible to join
skin and mucous membranes (13). Cyanoacrylates are also used for developing latent
fingerprints (25).
About 500 kg of methyl and 6000 kg of ethyl 2 cyanoacrylate were imported to Sweden
in 1993, for both household and industrial use. The medical use of cyanoacrylates in
Sweden is limited to small amounts of n-butyl 2-cyanoacrylate for closing minor skin
lesions.
Uptake, biotransformation, excretion
There are no data on human uptake, biotransformation, or excretion.
It has been shown in animal studies that cyanoacrylates can be absorbed via the digestive
tract and by skin after local application or subcutaneous implantation (4, 10, 30, 50, 51,
55, 60, 72). No information on uptake by inhalation was found in the literature.
Uptake was studied by applying 3-14C-labeled methyl, n-butyl, and n-heptyl 2-
cyanoacrylate to intact skin of rats (Sprague-Dawley). The methyl homologue was
eliminated most rapidly: 4.2% of the total applied radioactivity was excreted in urine within
five days, compared to about 0.2% for each of the other two homologues. Application on
skin after peeling it with a dermatome yielded values three to four times this high (50). In
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studies of the breakdown of methyl 2-cyanoacrylate-3-14C implanted under the skin of male
rats (Walter Reed) it was found that 6.6% of the applied dose remained at the implantation
site after 154 days and that excretion was 46.1% in urine and 5.5% in feces. No
radioactivity was detected in liver, kidneys, spleen, brain, muscle or fat (10). Comparable
results were obtained with n-butyl 2-cyanoacrylate-3-14C in a similar study of male rats
(Sprague-Dawley) (55). However, after 154 days 91.7% of the substance remained at the
site of implantation, and total radioactivity excreted in urine was 2.3% and in feces 0.71%.
Guinea pigs (Hartley) absorbed methyl 2-cyanoacrylate-2-14C rapidly from a full-
thickness skin incision that was closed with the adhesive (60). Most of the radioactivity
was eliminated in urine, with small amounts in feces, exhaled air (as CO2) and the scab on
the sore. After 4 and 18 days some radioactivity was detected in liver, kidneys, spleen,
heart, brain and blood, but after 64 days the radioactivity had subsided to base levels. After
107 days the cyanoacrylate had been absorbed almost completely from the site of the
incision.
To trace the breakdown pathways, methyl 2-cyanoacrylate-2-14C, -3-14C and -14CN
labeled monomers were implanted under the skin of mixed-breed dogs and metabolites in
urine were studied (72). According to the authors, the results indicate that cyanoacrylate is
broken down with the formation of formaldehyde and through ester hydrolysis.
Uptake of 14C-labeled methyl and n-butyl cyanoacrylates from the digestive tracts of
Sprague-Dawley rats was demonstrated by measuring radioactivity in urine (51). Uptake
could be demonstrated when the cyanoacrylates were applied directly to intact mucous
membranes in the mouth and also when polymerized methyl and n-butyl cyanoacrylate
were applied as powder directly in the stomach. Both methods of administration yielded
higher values for the methyl homologue than for the butyl homologue.
In one study it was shown that about 5% of the cyan groups in methyl 2-cyanoacrylate
implanted under the skin of rats or dogs is metabolized to thiocyanate and excreted in urine
(31). These results, however, could not be duplicated in another study (30).
Toxic effects
General toxicology (animal data)
Inhalation: The LC50 was estimated to be 101 ppm for rats that were exposed to methyl 2-
cyanoacrylate for 6 hours (1). Repeated inhalation of 31.3 ppm methyl 2-cyanoacrylate, 6
hours/day, 5 days/week for a total of 12 exposures, caused only a slight retardation in
weight gain. There was no nasal or tracheal damage and no visible evidence of systemic
toxicity. Nor could changes be noted in rats exposed to 3.1 ppm on the same schedule (1).
Dermal administration: The estimated LD50 for methyl 2-cyanoacrylate applied to the skin of
guinea pigs is › 10 ml/kg body weight (1).
In another study, n-butyl 2-cyanoacrylate was implanted under the skin of beagles (400
mg/kg) and liver function was monitored for 6 months. No negative effects on liver
function were observed, nor were any pathological effects observed on other vital organs at
autopsy (24).
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Oral administration: The LD50 for rats given oral doses of methyl 2-cyanoacrylate was
estimated in one study to be 1.6 to 3.2 g/kg body weight (1).
In another study, attempts to estimate the LD50 for methyl or butyl cyanoacrylate were
not successful. After polymerization, the cyanoacrylates were ground to a powder which
was suspended in water and given orally to rats. The powder in amounts of 1.4 and 2.1 g
was tolerated, but larger amounts made the animals vomit. Rats injected with liquid
cyanoacrylate in amounts ranging from 0.1 to 1 ml showed no indications of poisoning
(22).
Oral administration of poly(methyl 2-cyanoacrylate) to Sprague-Dawley rats and beagles,
in doses of 50, 100 or 200 mg/kg body weight/day for 90 days, yielded no clinical,
macroscopic or histological indications of systemic poisoning (54). Animals of both sexes
were studied.
Unweaned Sprague-Dawley rats of both sexes were fed with polymerized n-butyl 2-
cyanoacrylate which had been ground to powder, up to 6.4 g/day for 10 days. The rats
showed normal weight gain during a subsequent 90-day observation period. No lethal dose
level was reached, and examination revealed no macroscopic or histopathological changes
caused by the substance (52).
Other means of administration: The acute toxicity of Aron Alpha (98% ethyl cyanoacrylate;
2% methacrylate and hydroquinone together) was tested on Wistar rats by intraperitoneal
injection (49). The animals were observed for a week. The LD50 was determined to be 6.76
ml/kg.
Nanoparticles (diameter »  0.4 m m; 9.2 ml/mg suspension) of poly(n-butyl 2-
cyanoacrylate) and poly(isobutyl 2-cyanoacrylate) were injected into the caudal vein of
NMRI mice. The LD50 was determined to be 198 mg/kg for the first substance and 230
mg/kg for the second (27). The injection medium alone, however, was somewhat toxic
(LD50 = 33.4 ml/kg).
General toxicology (human data)
The only information found in the literature was one case report describing a patient with
peripheral neuropathy (20). The authors attributed the patient’s symptoms to exposure to
cyanoacrylate vapor. The patient had a 20-year history of frequent exposure to other wood
and plastic glues at work, however.
Local tissue toxicity
Alkyl 2-cyanoacrylates have great potential as tissue adhesives in surgery and dentistry
because they polymerize on and adhere to living tissue and are biologically degradable. All
cyanoacrylates, however, are locally toxic to some extent. The degree of toxicity depends
on the amount and type of cyanoacrylate applied and the tissue it is applied to. The local
irritation and toxicity caused by these compounds at the site of application and in
surrounding tissue have been studied and described in detail, in both man and experimental
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animals. The initial histopathological findings after application of cyanoacrylates are
indications of acute inflammation, which later becomes chronic (46).
The mechanism for the local toxicity shown by cyanoacrylates is not known. It seems
that the tissue effects of cyanoacrylate adhesives might be due to the heat produced during
polymerization (23, 44, 74) and to liberation of toxic breakdown products including
formaldehyde, cyanoacetate (32, 36, 39, 70, 72) and alcohols formed by hydrolysis of the
ester bond (37, 72). The more severe local toxicity observed for alkyl cyanoacrylates with
short chains (the methyl and ethyl derivatives) is assumed to be due to the fact that they
break down more rapidly than those with longer chains, which would lead to a locally
higher concentration of toxic breakdown products (37, 39). It has also been suggested that
the monomer itself has a direct toxic effect (3, 16, 61).
Irritation and sensitization
Irritation: There is a published study from 1968 (45) that describes symptoms of irritation
in 14 volunteers exposed to methyl 2-cyanoacrylate vapor in concentrations of 1 to 60 ppm.
The odor threshold was between 1 and 5 ppm for most of the subjects. Irritation of throat
and nose usually occurred at about 2 to 3 ppm, and smarting, irritated eyes at about 4 ppm
(see also Table 1). In another study, it was found that 10 to 50% of attentive persons can
detect the odor of 2 ppm methyl 2-cyanoacrylate (2).
Working conditions in a factory where beads and stones were mounted with methyl 2-
cyanoacrylate glue were studied for 5 years (38). Employees showed symptoms of
irritation, including contact dermatitis and inflammatory changes in nose, throat and
conjunctiva. Exposure to cyanoacrylate vapor was measured in an experimental work
situation, and was found to be 2 mg/m3 (0.4 ppm). An air purification system was installed
and semiautomated work methods were introduced, and there were no symptoms of
irritation during a subsequent observation period of 2 years.
A group of workers at an electronics factory who were exposed to a glue containing ethyl
2-cyanoacrylate developed irritative dermatitis on their faces (9). The outbreak occurred
when humidity at the workplace was fairly low. When the humidity was raised above 55%
no further outbreaks occurred. The authors conclude that the alkyl cyanoacrylate monomers
in vapor polymerize to an inert material with help of the water in the air. The conclusion is
in agreement with another study which reports that a woman who suffered from asthma
induced by exposure to cyanoacrylates at work felt some relief on the days a humidifier
was turned on (41).
Methyl 2-cyanoacrylate causes mild irritation on direct contact with skin (1,71). If large
amounts of cyanoacrylates come into contact with skin, the heat liberated by polymerization
can cause burns (18, 74).
Skin sensitization (type IV allergy): In a study of guinea pigs (Hartley) using a sensitization
method described by Polak et al (58), neither methyl nor butyl 2-cyanoacrylate gave rise to
contact sensitization (56).
It was long believed that cyanoacrylates could not cause skin sensitization because of
their extremely rapid polymerization and the binding induced by water and other
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nucleophilic groups in the epidermis. During the past decade, however, 13 case reports
have been published in which cyanoacrylates are suspected to have caused skin
sensitization (5, 8, 17, 19, 26, 57, 64, 65, 68).
In 9 of these cases ethyl 2-cyanoacrylate was reported to be the cause, and in the other
cases the cyanoacrylate was not specified. It has been proposed, however, that the
observed allergic reactions might have been caused by other acrylates, which are found in
small amounts as contaminants even in the purest cyanoacrylate preparations (26).
Considering the widespread use of cyanoacrylates in industries and households,
sensitization seems to be rare, which would indicate that cyanoacrylates are not particularly
strong skin sensitizers. Sensitization to cyanoacrylates may be more common than
previously believed, however, since they have been neglected as possible sensitizers and
are not included with other acrylates in skin sensitization tests. A further reason may be the
difficulty of diagnosing a contact allergy by using a patch test (8).
Respiratory sensitization (type I allergy) and asthma: There are two assessments of the
health risks to workers occupationally exposed to ethyl cyanoacrylates.
The first was made at a factory producing auto parts, which employed about 90 workers
(33). In the area where parts were glued with cyanoacrylate, the concentration of airborne
ethyl cyanoacrylate was measured 4 times: twice at breathing height, about 30 cm from the
nose of the worker using the glue; and twice in the vicinity of the application, about 60 cm
from the worker’s nose. The ethyl cyanoacrylate concentrations, determined according to a
method described by McGee et al (45), were 4.4, 4.6, 4.6 and 4.6 mg/m3 (»  1 ppm).
Sixteen workers exposed to ethyl cyanoacrylate on some occasion were given a
questionnaire. Those who worked with cyanoacrylates reported slightly more upper
respiratory symptoms than workers in the same factory who were exposed to lead. Some
of the workers (the exact number is not given) described symptoms indicating a possible
asthmatic reaction, which often appeared in the evenings or nights after they had been
working with cyanoacrylate. The authors concluded that exposure to ethyl cyanoacrylate
causes acute irritation of mucous membranes and possibly sensitization of lungs.
The other study was made at a factory with about 80 employees, in which industrial,
household and automotive products were manufactured (40). Ethyl cyanoacrylate was the
primary exposure, but there was also some suspicion of exposure to methyl ethyl ketone.
Ten measurements were made of ethyl cyanoacrylate vapors at breathing height over the
workbenches in the hall where the glue was used. Concentrations, determined by the
method described in McGee et al (45), ranged from not detectable (‹ 0.1 mg/m3) up to 1.6
mg/m3 (0.3 ppm). A questionnaire was filled out by 73 workers, 21 of whom reported that
they worked with cyanoacrylate for at least 1 day per week. Symptoms such as wheezing,
tightness in the chest and /or shortness of breath were reported by 26 workers. Health
examinations were given to 23 of those who reported symptoms and 20 who did not report
symptoms. Eight of those examined were diagnosed as having work-related asthma,
meeting the criteria used for diagnosis of asthma. The authors considered it impossible to
determine whether the ethyl cyanoacrylate was the cause of the work-related asthma, but
recommended that exposure be reduced.
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Twenty-six case reports of cyanoacrylate-induced asthma have been published, all but
one of which were attributed to occupational exposure (15, 28, 29, 41, 47, 62, 63, 67).
The cyanoacrylate was reported in one case to be methyl 2-cyanoacrylate, and in 8 cases to
be ethyl 2-cyanoacrylate: in the other cases the type was not specified. The duration of
exposure before the appearance of symptoms ranged from 1 week to 14 years. In only one
case (62) which was diagnosed as cyanoacrylate-induced asthma, it was reported that
exposure levels for ethyl cyanoacrylate vapors never exceeded 0.2 ppm (1.0 mg/m3) at
breathing level at and around the workbench. One case of urticaria triggered by an
unspecified acrylate has recently been reported (28).
The basic mechanism behind cyanoacrylate-induced asthma/respiratory disease is not
known, but an immunological etiology has been proposed. Prick tests given to patients
have failed to support this hypothesis, however, and there is no evidence of a specific IgE-
mediated reaction. An irritative mechanism can therefore not be excluded (63).
Mutagenicity, carcinogenicity, reproduction toxicity
Methyl 2-cyanoacrylate and adhesives containing methyl 2-cyanoacrylate have been shown
to be mutagenic in Ames’ tests with Salmonella typhimurium (TA 100), both with and
without microsomal activation (3, 61). Methyl 2-cyanoacrylate vapor was also shown be
mutagenic to TA 100 in a modified Ames’ test for volatile compounds (3, 61). No
mutagenic effects were observed in tests with ethyl, allyl, isobutyl, or n-butyl derivatives
or with pre-polymerized methyl 2-cyanoacrylate. Methyl 2-cyanoacrylate also had a
mutagenic effect in another Salmonella test (the strain was not specified), whereas 2-
ethylhexyl 2-cyano-3,3-diphenyl acrylate yielded negative results (75). In one study (42) n-
butyl 2-cyanoacrylate was found to have a weak, dose- and monooxygenase-dependent
mutagenic effect in one of six Salmonella strains (TA 1537) in an Ames’ test, but it was not
shown whether the mutagenicity was due to the cyanoacrylate, a blue dye or other
additives.
Several long-term cancer studies of cyanoacrylates have been made with mice (43), rats
(7, 21, 22, 43, 53, 54, 59, 66), rabbits (69), dogs (12, 34, 43, 53, 54) and monkeys (34,
35). In all cases, single doses of cyanoacrylates have been injected, sprayed or dropped in
or on various organs such as liver or skin. In four of the studies, all of which were with
rats, evidence was found of neoplastic changes caused by methyl 2-cyanoacrylate injected
subcutaneously (53, 54), n-butyl 2-cyanoacrylate implanted under skin and peritoneum
(59), isobutyl 2-cyanoacrylate implanted on the ventral side of the liver (7) and of an
unspecified alkyl 2-cyanoacrylate injected subcutaneously (21). It has been questioned
whether these findings are relevant to human exposures, and some researchers (6, 7, 13,
22, 69) believe that the observed carcinogenic qualities of cyanoacrylates represent an
Oppenheimer effect (48), i.e. a carcinogenesis caused by foreign bodies, which can be
induced by many different polymers (polyvinyl chloride etc.) and which is not specific for
the chemical characteristics of the polymer. No information regarding carcinogenic effects
of cyanoacrylates on humans was found in the literature.
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Only one study of the reproduction and/or fetotoxic effects of cyanoacrylates was found
(43). The report describes the absence of effects on the second generation of rats, which
were observed for 6 and 12 months, when the livers of their parents had been sprayed with
butyl or isobutyl 2-cyanoacrylate.
Dose-effect / dose-response relationships
The acute irritative effect of methyl cyanoacrylate vapor on eyes and mucous membranes
was studied under experimental conditions by McGee et al (45). The relationships between
the vapor concentration in air and the symptoms reported by the subjects are summarized in
Table 1.
Another study (38) reports symptoms of irritation in workers in a factory where
exposure to cyanoacrylate vapor, as estimated in an experimental work situation, was 2
mg/m3 (0.4 ppm).
Available data are altogether too sparse to allow determination of other dose-effect or
dose-response relationships (for skin sensitization, asthma/respiratory disease etc.), since
most of the reports contain no quantitative data on exposure. One report describes a woman
who, after 4 or 5 months of work with glue containing ethyl cyanoacrylate, developed
itching and pain in the nose, dry cough, chronic rhinitis and a feeling of tightness across
the chest. Air samples taken at breathing height over her work station showed that the
concentration of cyanoacrylate vapor did not exceed 0.2 ppm (62). Two studies report
symptoms of mucous membrane irritation and asthma in workers exposed to ethyl
cyanoacrylate. Measurements of ethyl cyanoacrylate vapor in locales where the glue was
used indicated concentrations ranging from not detectable to 1.6 mg/m3 (0.3 ppm) in one
case (40) and to 4.6 mg/m3 (»  1 ppm) in the other (33).
Table 1. Dose-response relationships for acute effects of exposure to cyanoacrylate
vapor, as reported by 14 volunteers exposed to cyanoacrylate vapor concentrations ranging





1 – 5 Odor threshold
2 – 20 Irritation of nose and throat
4 – 15 Irritation and burning in eyes
› 20 Runny nose, watery eyes
50 – 60 Pronounced irritation of eyes and nose, indications of painful eye irritation;
   a few hours after the exposure 2 of the subjects developed vision
   disturbances that lasted 2 hours
________________________________________________________________________
* There was considerable individual variation, and the given exposure levels are rough
approximations of the threshold values that apply to most of the subjects.
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Conclusions
The critical effects of both short-term and long-term exposure to cyanoacrylates are
irritation of skin and mucous membranes and induction of asthma / respiratory disease.
Only a few reports give air concentrations, and it is therefore difficult to determine the level
at which symptoms appear.
Judging from human data, cyanoacrylates can be suspected of being contact allergens.
However, there are few case reports of allergic contact eczema.
Cyanoacrylates have been shown to be carcinogenic in studies with rats, but the
relevance of these findings to human exposures has been questioned.
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Consensus Report for Potassium Aluminum
Fluoride
June 4, 1997
Potassium aluminum fluoride (KxAlyFz) is a flux used in soldering aluminum at a few
companies in Sweden. The flux contains a small amount of potassium aluminum
tetrafluoride (KAlF4), which at room temperature is a solid powder (1).
This report is based on two articles (1, 2), both of which report that exposure consisted
exclusively of potassium aluminum tetrafluoride (KAlF4), although the primary exposure
was actually to potassium aluminum fluoride (KxAlyFz).
Physical and chemical data.
CAS No: 60304-36-1
Systematic name: Potassium aluminum fluoride
Trade name: Nocolok 100 flux
Formula: KxAlyFz
Melting point: 560 – 577 ° C
Density: 2.8 g/cm3
Solubility in water: 4.5 g/l (20 ° C)
Uptake, biotransformation, excretion
There is no available information on uptake, biotransformation or excretion.
Toxic effects
One company has been using potassium aluminum fluoride (KxAlyFz) as a soldering flux
for about ten years. The items to be soldered were treated with a solution of KxAlyFz in
water. When this solution dries it leaves the surface covered with a fine powder of KxAlyFz
that functions as a flux. After the items were assembled they were soldered in an oven. Ten
persons at this company were exposed to KxAlyFz at the same time. Over a ten-year period
22 exposed workers visited the regional occupational health clinic because of respiratory
problems. The latency time before the problems appeared ranged from 1 to 60 months
(median 6 months). Nearly all of the workers (21 of 22 ) were bothered by coughing or
tightness in the chest. Nine reported nasal irritation. Five had irritated eyes, and four had a
skin rash. Five of the 22 had a family history of atopia. The respiratory problems
diminished or disappeared after termination of exposure (2).
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Sixteen of the 22 workers were tested for bronchial hyperreactivity. Methacholine tests
showed pronounced hyperreactivity in two of those tested. During the test the VTG
(Volume of Trapped Gas) increased abnormally in 8 of the 16 workers tested. VTG is a
method of studying conditions in the small respiratory passages. Three persons had a
serum content of IgE that exceeded the reference value (› 100 kU/l) (2). IgE antibodies
specific for aluminum or aluminum compounds could not be identified. Prick tests were
negative (personal communication, Ulf Hjortsberg, University Hospital, Malmö, Sweden,
February 1997).
Measurements made during the years 1985 – 1988 showed levels of total respirable
particles around 1.1 mg/m3 (median concentration; range 0.6 – 2.4 mg/m3), of which about
0.3 mg/m3 was fluoride (median; range 0.1 – 0.9 mg/m3). After installation of a central
exhaust system in 1988 total respirable dust dropped to 0.7 mg/m3 (range 0.4 – 1.3
mg/m3) and total respirable fluoride dropped to 0.1 mg/m3 (range 0.03 – 0.3 mg/m3).
Mutagenicity, carcinogenicity, teratogenicity
There are no data on mutagenicity, carcinogenicity, or teratogenicity of KAlF4 for either
humans or animals.
Dose-effect / dose-response relationships
Coughing and/or a feeling of tightness across the chest were common symptoms among
workers exposed to KxAlyFz in connection with soldering of aluminum. Exposure to
KxAlyFz appears to increase bronchial hyperreactivity (2). It seems likely that the
hyperreactivity is an irritative rather than an allergic reaction. The median concentration of
respirable particles was 1.1 mg/m3 during the years 1985 –1988 and 0.7 mg/m3 after 1988.
The median concentration of respirable fluoride particles was 0.3 mg/m3 during the years
1985 – 1988 and 0.1 mg/m3 after 1988 (2). No reduction of symptoms could be
established with certainty at the lower concentration (personal communication, Ulf
Hjortsberg, University Hospital, Malmö, Sweden, February 1997).
It is impossible to establish a NOAEL (No Observable Adverse Effect Level).
Conclusions
Information on the risks of exposure to KxAlyFz is based solely on one case report from
one company. The critical effect of occupational exposure to KxAlyFz is respiratory
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Consensus Report for Inorganic Manganese
June 4, 1997
This report is based on previously published Consensus Reports (19, 30, 31), on some
international surveys of the literature (2, 53), and on original works published from 1990
to August, 1995.
Chemical and physical data. Uses
Manganese is used to form alloys with several other metals. Occupational exposure to
manganese dust may occur during production of e.g. steel, glass, and welding electrodes,
and during welding – especially welding of alloys. Some dry-cell batteries contain
manganese dioxide, and various manganese salts are used as catalysts, fluxes, oxidants and
reducing agents. Some pesticides, fertilizers, bleaches and disinfectants also contain
manganese salts. Manganese occurs with oxidation numbers of +II to +VII
Manganese is an essential trace element in all living organisms.
Table 1. Chemical and physical data for manganese, manganese oxides and manganese
chloride.
________________________________________________________________________
Substance Formula CAS No. Molecular
weight
Soluble in water
Manganese Mn 7439-96-5   54.94 no
Manganese
chloride
MnCl2 7773-01-5 125.84 yes
Manganese
dioxide
MnO2 1313-13-9   86.94 no
Manganese
tetroxide
Mn3O4 1317-35-7 228.79 no
________________________________________________________________________
Uptake, distribution, excretion
No information on skin uptake of inorganic manganese compounds was found in the
literature. Uptake of manganese via the lungs was demonstrated in a study in which
volunteers inhaled an aerosol containing MnCl2 and MnO2. The amount of manganese
taken up via the lungs was not reported, but it was reported that 40 to 70% (average 60%)
of inhaled manganese was recovered in feces during the four days following the exposure
(33). No differences in uptake or excretion between the two substances could be shown.
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A daily dietary intake of about 2 to 3 mg manganese is considered adequate by WHO
(53), and a person’s normal daily intake in food has been estimated to be between 2 and 7
mg (33). The degree of absorption is affected by both the amount taken in and the amount
in tissues (39). People and experimental animals absorb only 3 or 4 percent of the amount
of manganese in food (13, 33). It has been observed in anemic subjects that iron deficiency
increases absorption of manganese from the digestive tract (33). In animal experiments, it
has been shown that simultaneous ingestion of ethanol and manganese increases both the
uptake and the toxicity of the manganese (45).
Occupational exposure is mostly due to inhalation of dust containing manganese. There
are no data that clarify interaction between uptake via lungs and uptake via the digestive
tract. The regulation of uptake that occurs via the digestive tract might be circumvented,
allowing considerably greater amounts of manganese to be absorbed by the body.
The adult human body contains an estimated 12 to 20 mg manganese (13), with the
highest concentrations in liver, large intestine and kidneys (about 1 m g Mn/g wet weight)
(43). Manganese passes the placental barrier, and levels in the fetus and the mother are
therefore about the same (43). In blood, manganese is transported mostly bound to proteins
(20).
It has been shown in animal experiments (23) that manganese is excreted mostly (95
–99%) by active transport via the gall bladder: 99% of an intravenous dose was excreted in
feces within five days. Increased intake of manganese increases the rate of excretion (39).
Persons not occupationally exposed excrete only about 6% (with large individual variation)
in urine (42).
Reports of the biological half time vary considerably (19). Whole-body half time after
inhalation of 54MnO2 was reported to be about a month for healthy, unexposed subjects,
and about two weeks for miners exposed to manganese (34).
Toxic effects
Animal data
Most animal studies are of two compounds: manganese dioxide (MnO2 ) and manganese
chloride (MnCl2 ). Table 2 presents a summary of a number of animal studies with
exposure to manganese dioxide, and Table 3 presents some studies with the more readily
soluble manganese chloride. Both tables are organized according to method of
administration. Only a few of these studies cover inhalation exposure. Regardless of how
the animals are exposed, manganese affects primarily their nervous systems and respiratory
organs – the same organs it affects in people. There is apparently no difference in the types
of effects caused by the two substances. It is possible that manganese chloride, the more
soluble of the two, produces effects at lower exposures.
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Table 2. Effects of exposure to manganese dioxide observed in experimental animals.
________________________________________________________________________








Aerosol, 0.011, 0.112 and
1.15 mg Mn/m3
24 hrs/day for 9 months
Accelerated growth, elevated Hb levels
at high dose.
Dose-dependent elevation of Mn levels
in kidneys, lungs, spleen, blood.
No exposure-related effects on lung




Observation up to 18 months
Emphysema after 1-2 hours, alveolar
inflammation, large numbers of
macrophages.






Observation up to 180 days
Day 7: proliferation of macrophages.




Observation up to 8 months
Enzyme effects in testes; after 8




Observation up to 24 months
Paralysis of rear legs.
Neuron degeneration in brain.
5
Macaque Subcutaneous:
0.25, 0.5 or 1.0 g, once a
week for 9 weeks.
Observation up to 3 months
Low-dose group: hand tremor,
disturbed balance after about 50 days.
Medium-dose group: Same after about
35 days.




0.1 g once a month for 26
months




0.4 g 11 times in 4 months +
1 time 12 months later




2 g + 2 g two months later.
Observation up to 24 months
Indications of poisoning after 9
months.
Brain damage after 14 months,
particularly in some areas
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Mouse In food:
 2g Mn/kg food, 100 days
Reduced numbers of white blood cells 24
Mouse In food:
2g Mn/kg food, 12 months
Reduced dopamine level in brain.




Table 3. Effects of exposure to manganese chloride observed in experimental animals
________________________________________________________________________





Neuron degeneration after 120 days.
4, 10
Rat Intraperitoneal:
8 mg/kg b. w./day
120 days
Enzyme effects in brain. 46
Monkey Intravenous:
5-10 mg/kg b. w., 6-7 times
at intervals of at least a week;
total time 450 days, total
dose 50-60 mg/kg
Lethargy, Impairment in motor
performance,




3.5 mg/kg b. w./day
30 days
Degenerative changes in testes. 22
Rat Intratracheal:
1 ml 5% or 0.5% solution
Observation 8 days
5%: All animals died of lung edema
within a few minutes.




12.5, 25, 50 or 100 m g
Dopamine reduction lasting at least 90





Enzyme effects in brain.
Neuron degeneration.
7
Rat In drinking water:
1 or 10 mg/ml
Observation up to 360 days
Enzyme effects in brain. 3, 8
Mouse Mothers: 5 mg/ml in
drinking water
Pups: via milk, followed by
3 m g/ml in drinking water
Increased motor activity.
Enzyme effects in brain.
9
Mouse In feed:
2 g Mn/kg feed
Observation 100 days
Slower growth.




Effects on the central nervous system
Several years of occupational exposure to high concentrations of manganese (usually over
1000 m g/m3) can cause manganism. The onset of the illness is marked by psychological
symptoms such as emotional instability, behavior disturbances and in severe cases even
hallucinations. This phase is followed by neurological symptoms: muscular weakness,
speech impairment, headaches and symptoms resembling those of Parkinson’s disease
(39).
Several studies of the CNS effects of occupational exposure to low concentrations of
manganese have been published in the past few years (11, 21, 29, 35, 40, 47). The studies
were initiated because effects at low exposure levels resemble those of clinical cases of
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manganism, but the threshold level for appearance of these effects is not known. The
results of these studies are summarized in Table 4.
In a study from Taiwan (21), psychometric tests were given to four small groups: 17
symptom-free manganese workers, 4 manganese workers with the diagnosis of
Parkinson’s disease; 8 patients with a diagnosis of Parkinson’s and no exposure to
manganese; and a control group of 19 persons. The relevance of this study is difficult to
assess, since the report is unclear on many points. The criteria for choosing the study
groups are not adequately described. ”Symptom-free workers,” for example, seem to have
been chosen simply on the basis of having no symptoms. The tests used are traditional
clinical tests designed to diagnose severe brain damage, and are definitely not as sensitive
as the tests used in other modern studies. For these reasons, the results of this study are not
included in the summary in Table 4.
In a Belgian study (40), 92 workers exposed to MnO2 in battery manufacture and 101
unexposed controls were examined in an attempt to establish the lowest level at which CNS
symptoms appear. The studied group consisted of fairly young workers (aged 22 to 50,
average age 31.3) with relatively short exposures (0.2 to 17.7 years, average 5.3). Their
current exposures to manganese in total dust and in the respirable fraction were measured
with personal monitors, and showed a geometric mean of 948 m g/m3 (range 46 to 10,840
m g/m3). The control group was recruited from a chemical processing industry in which
there was no known exposure to neurotoxic substances. Effects measured included
neuropsychological symptoms, respiratory symptoms, lung function, psychological
performance, various biological parameters (serum content of calcium, iron and some
hormones, standard hematological analysis), and concentrations of manganese, lead,
cadmium and mercury in urine and blood. Two exposure indices for total occupational
exposure were calculated for each worker: one based on Mn in total dust (range 191 –
27,465 m g Mn/m3 x year) and one based on Mn in the respirable fraction (40 – 4433 m g
Mn/m3 x year). There was no statistically confirmed connection between these exposure
indices and the manganese content of blood or urine. When the workers were divided into
six groups according to manganese in urine, however, a correlation with the measured air
concentrations of Mn could be established.
Regarding effects on respiratory organs, there were no differences between the exposed
group and controls, neither increase of symptoms nor effects on spirometry. Nor was it
possible to determine a difference between the groups with regard to reported CNS
symptoms. However, there were clear differences in results on several performance tests
(reaction time, eye-hand coordination and hand tremor), on which the exposed group did
less well than controls.
No significant correlations could be established between biological concentrations and
either exposure index (respirable fraction or total dust). For the results of the reaction time,
eye-hand coordination and hand tremor tests, however, there was a definite correlation
between the exposure indices and the magnitude of the effects. Abnormal test results were
clearly more prevalent in groups with higher exposure. The authors considered it
impossible to identify a threshold value for the appearance of effects, and used logistic
regression to determine the exposure at which there was a significant increase in the risk of
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effects on hand tremor. The regression analysis showed that hand tremor increased
significantly when the total dose exceeded 3575 m m Mn/m3 x year for total dust and 730 m g
Mn/m3 x year for the respirable fraction. Dividing these results by the average exposure
time yields levels of 674 m g/m3 for total dust and 138 m g/m3 for the respirable fraction. It
should be borne in mind that this estimate of the critical exposure level is based on data
from a group of young workers with relatively little time in exposed jobs.
A small group of 17 manganese-exposed workers was studied at two plants in Singapore
(11, 12) where manganese ore was ground and packed for further shipping. Before 1985
exposure levels were above 5000 m g/m3, but since that date exposure to manganese in total
dust has not exceeded 1000 m g/m3 and had gradually been reduced to about 30 m g/m3 by
1991. The geometric mean for manganese concentrations in air during the 1981 –1991
period was 1590 m g/m3  The workers had been employed an average of 7.4 years (SD =
4.3) and 12 of those examined had been employed for more than five years when the study
was made. A control group was recruited from administrative staff at a hospital. No
differences between exposed subjects and controls could be observed in clinical
neurological examination or in tests of neural conductivity in motor and sensory nerves.
The subjects exposed to manganese reported more vegetative symptoms and did not
perform as well on tests of motor ability, coordination, manual dexterity, hand tremor and
memory. The authors conclude that ”…this result may be suggestive of an early Parkinson-
like disorder.” Thirteen of the exposed subjects and 16 controls were also given balance
tests. Clear differences between exposed subjects and controls could be noted on some of
these parameters also (12). No correlation between exposure level and effect could be
established.
In a Canadian study (35) at a foundry where manganese alloys were produced, 74
exposed workers were compared to paired controls. The exposure, which averaged 16.7
years, was to manganese in the form of oxides, and air concentrations averaged 1180
m g/m3 for total dust and 120 m g/m3 for the respirable fraction (geometric means were 220
and 30 m g/m3 respectively). The controls were recruited from the same town, and the
groups were matched with regard to a fairly large number of relevant variables. A large
battery of tests were used to measure effects. They included motor tests (finger tapping,
hand tremor, grip strength, eye-hand coordination), sensory tests (visual acuity, color
discrimination, contrast sensitivity, odor threshold and vibration threshold), alertness,
concentration and memory tests (number memory, word memory, coding, simple reaction
time and choice reaction time), cognitive flexibility and mood (POMS). The results showed
effects on several reported symptoms commonly associated with manganese exposure,
notably fatigue, forgetfulness, concentration difficulties and reduced potency. Effects were
also seen in several of the performance tests, including motor tests, in which the exposed
group performed less well than controls. The results of some cognitive tests showed
similar differences between the groups. The authors conclude that ”These findings, which
are consistent with current knowledge on the site and mechanisms of manganese activity in
the brain, suggest that manganism probably progresses infraclinically on a continuum;
initial manifestations can be observed in well-designed population studies, using sensitive
testing methods.” No analyses of dose-response or dose-effect relationships were given.
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In an Italian study at a foundry where manganese alloys were produced (29), 58 exposed
workers were tested during a period of layoffs. The workers were divided into three
groups according to exposure level, which was measured as m g Mn/m3 (total dust). One
group consisted of workers from the ovens, where levels during the previous decade had
dropped from 1590 to 270 m g/m3; one group was maintenance workers, where levels had
dropped from 319 to 124 m g/m3; and one group was from other parts of the factory, where
levels had dropped from 70 to 27 m g/m3 (all these values are geometric means). The
authors report that 95% of the manganese was in the form of oxides, and that the respirable
fraction made up 50 – 60% of total dust. The time between the most recent exposure and
the examination ranged from 1 to 42 days (median 13 days). Manganese concentrations in
blood and urine were used as a measure of internal exposure. A cumulative exposure index
was also calculated for each subject. No control group was used in this study.
The effects of exposure were measured with seven different psychological performance
tests. The groups exposed to the two higher manganese concentrations did less well on the
tests. The inferior performance was seen on tests of addition, coding, finger-tapping and
memory. A dose-effect correlation could be established for several of the test results: the
results of four of the tests were correlated to manganese in blood, and one of the test results
was correlated to manganese in urine and to the calculated cumulative exposure index. The
correlations showed a tendency to increase with both duration of employment and duration
of layoff.
A Swedish study of welders (48) reports results for a small group (N = 12) exposed to
manganese who were compared with welders working with ordinary steel (N = 39). These
welders work on tracks for the Swedish state railways, and one of their jobs is to put a
layer of manganese on the rails after they have been laid, using a special electrode. The
work is dependent on the outdoor temperature and can only be performed during warm
weather, and is done for only a few weeks per worker per year. The effects were measured
in late winter. Exposure was measured as the number of hours at the arc with manganese
welding, and as manganese in blood. Blood lead was also checked, as was aluminum in
blood and urine. Only three measures of air concentrations have been made around this
type of work, and these yielded time-weighted averages of 100, 500 and 900 m g/m3. The
results of this study indicated no differences between manganese welders and other welders
with regard to manganese content in blood. No differences in lead or aluminum were
observed, either. Regarding effect measures, the manganese welders had more symptoms
involving the peripheral nervous system and less restful sleep, and had poorer scores on
five different measures of motor function.
A group of 35  foundry workers, exposed to about 460 m g/m3 (geometric mean; range
46 – 980 m g/m3 ) for an average of 14.5 years were recently examined. The examination
included a test of motor function (28). Exposed workers tended to perform less well than
controls, and a dose-response relationship could be established since performance on that
test correlated with manganese concentration in blood (r = 0.42).
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Effects on respiratory organs
Inhalation of MnO2 or Mn3O4 causes an inflammatory reaction in the lungs (44). This
reaction does not seem to be specific for manganese, however, since it also occurs with
inhalation of particles of other substances (2). An increased vulnerability to bacterial
infection seems to be a secondary effect of the lung irritation (1).
Two Belgian studies of occupational exposure to manganese report both symptom
assessments and lung function tests (40, 41). The workers in one of the studies (41) were
exposed to manganese in the form of both salts and oxides. The exposure level was 940
m g/m3 (geometric mean), and the average duration of employment was 7.1 years (range 1–
19 years). An elevated frequency of respiratory symptoms was documented for those
exposed to manganese, both smokers and non-smokers. There was also an elevated risk of
acute bronchitis. On the spirometry tests, manganese had an effect on FVC (Forced Vital
Capacity), though no dose-response relationship could be established. The results indicate
that manganese has slight effects on the respiratory passages at a level as low as about 1000
40
m g/m3 . The subjects in the other study (40) were workers exposed to manganese oxides
only, and no differences were found in either the spirometry tests or symptoms, despite
about the same level of exposure (»  1000 m g/m3). The authors explain the different results
of these two studies with the different biological availability of water-soluble manganese
chloride and the sparingly soluble manganese oxides.
According to WHO (53), occupational exposures to air concentrations below 300 m g/m3
should have no effects on the lungs.
Other effects
Regarding hematological effects, there are some contradictory results in both human and
animal studies. The only effects reported from the well-controlled studies of recent years
are on the number of white blood cells. In a study of workers exposed to various
manganese salts (about 1000 m g/m3 ) in a battery factory (41), they were found to have a
higher number of white blood cells (neutrophilic leucocytes only) than controls (p ‹ 0.001).
Values exceeding the 95th percentile in the control group were found in 21% of the
exposed group. The difference could not be explained by smoking habits, since the number
of smokers was larger in the control group and the effects of manganese exposure and
smoking were independent of each other.
Elevated numbers of white blood cells have recently been reported in a group of  foundry
workers exposed to an average 460 m g/m3 (geometric mean; range 210 – 890 m g/m3 ) (28).
The average duration of employment in exposed jobs was 14.5 years. Elevated numbers of
neutrophilic leucocytes and lymphocytes were observed in the study. The difference can
not be explained by smoking in this case, either, since manganese was shown to have a
significant effect regardless of smoking habits.
Effects on fertility, libido and potency have been observed with occupational exposure to
manganese (26, 35, 52). In one study of 85 industrial workers exposed to manganese, they
were found to have lower fertility than a control group. The exposure level was 940 m g/m3
(total dust, geometric mean; range 70 – 8610 m g/m3 ). The number of children was lower
than expected in two of three age groups (16 – 25 and 26 – 35), but no effects were
observed in the third age group (36 – 45). In the Swedish study of foundry workers (52) a
reduced sex drive was one of two symptoms that differentiated the exposed group from
controls. In the Canadian study (35) made at a foundry where 74 workers were compared
with paired controls, the exposed group had a higher frequency of three symptoms:
”Difficulty in maintaining an erection,” ”Loss of libido,” and ”Difficulty ejaculating.” Some
support for effects on fertility is also provided by animal studies in which injections of
manganese dioxide or manganese chloride have affected enzyme activity in testes and
caused sclerosis in the ducts (4, 6, 21; see also Tables 2 and 3).
Mutagenicity, carcinogenicity, teratogenicity
Manganese in ion form can replace magnesium in DNA polymerase and thus disrupt DNA
replication (14), but it is not clear whether this constitutes a risk for genetic effects in
humans.
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There are only a few cancer studies of manganese, and the results are mixed. Exposure
via respiratory passages has not been associated with any form of cancer. In a cancer study
in which rats and mice were given manganese sulfate in food, the rats showed no indication
of cancer but the mice showed a marginal increase of follicular adenomas in thyroidea. The
feed given the mice contained 1500, 5000 or 15,000 ppm manganese sulfate, equivalent to
approximately 160, 540 or 1800 mg/kg body weight/day for males and 200, 700 or 2250
mg/kg/day for females (37).
Rats (Fischer-344) and mice (Swiss albino) given intramuscular injections of a solution
containing manganese dioxide or manganese in powder form showed no effects when
compared with controls. Each injection contained 3 or 10 mg manganese, and the animals
were injected up to nine times (18).
In the judgement of the EPA (15), available data do not provide an adequate basis for
assessing the carcinogenicity of manganese. The IARC has made no assessment of
manganese.
Dose-effect / dose-response relationships
Effects on respiratory passages and hematological parameters have been found at exposures
to 1000 m g/m3 or somewhat lower (total dust). Effects on the nervous system have been
demonstrated at total dust contents around 200 m g/m3. For the respirable fraction, effects
appear at concentrations around 100 m g/m3. It has not been possible to establish a threshold
value (NOAEL/LOAEL) for effects on the central nervous system.
Conclusions
The critical effects of occupational exposure to manganese are its effects on the nervous
system, which have been shown to appear at average levels around 200 m g Mn/m3 (total
dust).
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Consensus Report for Platinum and Platinum
Compounds
June 4, 1997
This report is based on a criteria document compiled jointly by the Nordic Expert Group
and the Dutch Expert Committee (DECOS) (46).
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Platinum (II) chloride PtCl2 10025-65-7 265.99 581 (d)









(NH4)2Pt Cl6 16919-58-7 443.87 380 (d)
Potassium
tetrachloroplatinate (II)








Na2PtCl6 16923-58-3 453.77 250 (d)
_____________________________________________________________
(d) = decomposes
Platinum is a silver-white, relatively soft precious metal (7, 23, 32). It is extremely
resistant to chemicals, and about the only thing that will affect it at room temperature is
aqua regia (28). Platinum has great ability to form complexes, and can form numerous
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different complexes with tetra- and hexa-coordination (16, 23, 32). The most common
valences for platinum are +2 and +4 (16, 60). Most of the tetrachloroplatinates are soluble
in water, whereas the hexachloroplatinates vary in this respect (77). The water-soluble
compounds include platinum (IV) chloride, platinum (IV) sulfate and hexachloroplatinic
(IV) acid (45, 77, 86).
Occurrence, use
Metallic platinum and platinum alloys are widely used in industry because they are very
good catalysts. The metal is used – to take a few examples – in the petrochemical industry
to upgrade the octane of gasoline, in the basic chemical industry for production of nitric
acid and sulfuric acid, and in the automobile industry in the production of catalytic
converters (7, 35, 60). Metallic platinum and platinum alloys are also used because of their
durability and resistance to corrosion at a range of temperatures, and are found in some
types of factory and laboratory equipment: electrochemical anodes, spinnerettes for viscose
fiber, crucibles for molten glass etc. Platinum is also used in the electronics industry and in
the production of jewelry, ceramic glass, dental material and medical implants (7, 16, 35,
60).
Hexachloroplatinic (IV) acid and some platinum salts are formed and used in refining
metallic platinum (from ores or in recycling) (4, 23, 64, 69). Hexachloroplatinic (IV) acid
and soluble platinum salts may also be used in the production of catalytic converters, in
plating on electrodes, wire, airplane components, jewelry etc., and in the photographic
industry (6, 22, 28, 31, 52, 74, 90).
Uptake, distribution, excretion
Daily intake of platinum in food is estimated in an Australian study (83) to be about 1.4 m g
Pt (1.15 – 1.73 m g Pt). In the same study, excretion in feces is reported to be 0.61 – 0.73
m g Pt /day, and in urine 0.76 – 1.07 m g Pt/day. This information leads to the conclusion
that quite a bit of the platinum taken in is absorbed, but further studies are necessary to
establish this with certainty. Uptake of platinum and platinum compounds in work
environments can occur via inhalation or by swallowing dust particles. Elevated platinum
levels have been reported in blood and urine of persons occupationally exposed to metallic
platinum, but no definite correlations between air concentrations and concentrations in
blood/serum or urine were found (1, 70). Slow excretion of the metal was indicated in one
study (1) in which little reduction of the platinum in urine and serum could be shown after a
brief exposure-free period (15 days).
Data from animal experiments indicate that uptake of orally administered metallic
platinum and various platinum compounds is small, but related to solubility and particle
size (2, 3, 13). In a study with rats, uptake of platinum (IV) chloride was roughly
estimated to be ‹ 1% of the dose (57, 58). No quantitative data on uptake of platinum via
inhalation were found. Excretion data (rats), however, indicate that minor amounts are
absorbed during short-term exposures (48 minutes) to metallic platinum, platinum (IV)
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oxide, platinum (IV) sulfate or platinum (IV) chloride (air concentrations 5 – 8 mg/m3 ),
but the relative amounts of uptake via lungs and digestive tract could not be determined
(59). Immediately after the exposures there was accumulation of platinum in the digestive
tract and respiratory passages. Most of it was excreted from the digestive tract within 24
hours, but elimination from the lungs was much slower. Platinum (IV) sulfate was
eliminated from lungs somewhat faster than the metal or the oxide. After exposure to
metallic platinum (7 – 8 mg/m3 ) the highest platinum concentrations were found in lungs,
trachea, kidneys and bone; very little platinum was found in brain tissue (59). After oral
administration of platinum to mice and rats, the highest concentrations have often been
found in kidneys (2, 3, 13, 26, 48, 57, 58, 65). Platinum has been identified in very small
amounts in fetuses (mice, rats) after administration of platinum as metal or salt (40, 50,




There are few reports of acute poisoning attributed to platinum exposure. In one case,
nausea, vomiting, diarrhea and leg cramps were reported about 12 hours after swallowing
600 mg potassium tetrachloroplatinate (II), and medical examination revealed acute kidney
damage, inflammation in stomach and intestines, mild hepatitis and other effects. The initial
serum concentration was 245 m g Pt/dl, and the urine concentration was 4200 m g Pt/L (90).
There are many reported cases of eye irritation, respiratory symptoms and/or skin
reactions (e.g. urticaria) resulting from occupational exposure to hexachloroplatinic acid
and some platinum salts (46). Duration of exposure before the appearance of symptoms has
ranged from one week to over 20 years (46). There are no reports of respiratory symptoms
attributed to exposure to metallic platinum (31, 44, 73, 87), and only one reported case of a
skin reaction (dermatitis) (72). It has sometimes been possible to show an immunological
etiology for these symptoms, usually with a prick test using platinum salts or by
identification of specific IgE antibodies in serum (in vitro) (46). In the other cases of
respiratory symptoms, a non-specific irritative effect of platinum salts can not be excluded
(9, 11, 88). The acute symptoms of allergy to platinum salts usually disappear when
exposure is terminated (47, 66), but there may be a residual non-specific hyperreactivity in
respiratory passages and/or a residual positive reaction to prick tests (4, 17, 54).
Dermatitis, which has been reported in employees at platinum refineries, is often attributed
to other irritating substances (14, 30).
Respiratory symptoms (sneezing, coughing, shortness of breath etc.) were reported in
52 of 91 workers (57%) in four refineries where platinum concentrations in air ranged from
0.9 to 1700 m g/m3 (21, 31). In one of the refineries, where measured air concentrations
ranged from 0.9 to 3.2 m g/m3, 5 of 7 workers reported minor symptoms such as sneezing
and runny nose (21, 31). In other older studies (51, 63, 66, 69) the estimated prevalence of
symptoms involving eyes, respiratory passages and/or skin in refinery workers ranges
from 60 to 88%, but no air concentrations of platinum are reported. In a retrospective
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cohort study (84), 91 workers were followed from 1973-1974 until 1980. There were 49
subjects (54%) with respiratory symptoms, and 22 of 84 persons (26%) had a positive
reaction to a prick test with platinum salts. It was shown that smokers have an elevated risk
of sensitization to platinum salts. No monitoring data are presented in this study.
A study of 107 workers who worked with recycling platinum in 1981 is described in
three other reports (4, 8, 17). Rhinitis was reported in 44%, and asthma in 29% of them
(the diagnoses were made after interviews with the subjects). A prick test with platinum
salts yielded a positive reaction in 14% of the subjects, and the prevalence was reported to
vary with the air concentration: e.g. sensitization to platinum salts was reported in two of
three (67%) workers in a part of the refinery where the average concentration was 27.1
m g/m3, but in only 2 of 14 workers (14%) in other parts of the refinery where the average
concentration was 10.7 m g/m3, and in 2 of 19 workers (11%) in the laboratories, where the
platinum concentration never exceeded 2.0 m g/m3 on any monitoring occasion (average
concentration 0.4 m g/m3). A strong correlation between smoking and a positive reaction on
the prick test was also reported in this study.
In the past few years the prevalence of symptoms in platinum-exposed workers has
generally been reported to be lower than it used to be. In one study (15), it is reported that
15 of 65 workers (23%) had work-related symptoms (conjunctivitis, rhinitis, cough,
shortness of breath), and that the symptoms were more common among personnel with
high platinum exposure than among those with moderate or low exposure (52%, 4%, 14%)
but further data on exposure levels were not given. The group with work-related symptoms
had normal lung function at the beginning of the week, but showed a decline (p = ‹ 0.05) in
some measures of lung function (FEV1, FEF25) as the work week progressed. Twelve of
64 workers (18.7%) had a positive reaction to platinum salts in a prick test: of these 12, 9
were in the group with work-related symptoms and 2 in the group with symptoms not
judged to be work-related. The air concentrations of platinum salts in total dust were
measured a few times in 1984 and 1986, and reported to be ‹ 0. 2 m g/m3 in 1984 and 0.08
– 0.1 m g/m3 in 1986 with stationary monitoring, and ‹ 0.05 m g/m3 with personal monitors
in 1986. It was also reported that 2.0 m g/m3, the exposure limit in force at the time, was
not exceeded.
In another study (55, 56), work-related symptoms (conjunctivitis, rhinitis, asthma, skin
reactions) were observed in 2 of 24 workers (8%) at a platinum refinery. Prick tests with a
hexachloroplatinate solution were given to 20 workers, and 4 (20%) had a positive
reaction. One of these was in the group with work-related symptoms, and three were in the
group with symptoms not classified as work-related (one of these, however, developed
work-related asthma after the study). It was reported that the risk of developing an allergy
to platinum salts did not increase with smoking, and it was shown that the workers in the
group with work-related symptoms had higher exposure to platinum salts than workers in
the other studied groups. No details were given regarding exposure levels, but it was
reported that the air concentration of platinum salts was generally below 0.08 m g/m3 (55,
56).
In an incompletely reported study of 261 workers who were followed for at least 2.5
years (1989-1992), it is stated that no cases of allergy were found in places where the air
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concentration of soluble platinum salts was below 0.01 m g/m3. A total of 8 persons (3%)
were reported to be allergic to platinum salts, but no monitoring data were presented. The
air concentrations were considered to be generally lower than average for platinum
refineries, however (53).
In one study (55), bronchial provocation tests with methacholine and platinum salts
given to 27 workers who had quit their jobs because of work-related symptoms revealed
effects on lung function in 22 of them. The authors state that the provocation dose was
equivalent to the amount that a worker inhales (2 x 10-8 g/minute) at an exposure level of 2
m g/m3, but no further details of the calculation are given.
Animal data
Different platinum compounds vary quite a bit in their acute toxicity. Water-soluble
compounds, however, usually have greater acute toxicity than insoluble compounds in the
same group (25, 26, 35, 60). LD50 values ranging from 25 to 240 mg/kg (rats) have been
reported for oral administration of e.g. ammonium tetrachloroplatinate (II), ammonium
hexachloroplatinate (IV), potassium tetrachloroplatinate (II), sodium hexachloroplatinate
(IV) and platinum (IV) chloride (25, 35).
Single injections of hexachloroplatinic (IV) acid, potassium tetrachloroplatinate (II),
potassium hexachloroplatinate (IV), or platinum (IV) chloride have resulted in extensive
kidney damage, severe histopathological changes in the thymus, and effects on enzymes
that regulate heme biosynthesis, drug metabolism or DNA synthesis (20, 27, 49, 61, 85).
Repeated oral administration of soluble platinum salts – platinum (IV) chloride, platinum
(IV) sulfate tetrahydrate, potassium tetrachloroplatinate (II) – has resulted in lower weight
gain, higher kidney weights, effects on liver enzymes and, at lower doses, reduced kidney
function and effects on blood parameters (26, 27, 58, 65). Oral administration of metallic
platinum has been reported to increase the number of red blood cells (12, 13).
A few inhalation studies were found. In a sketchily reported Russian study (67), effects
on several parameters were seen in rats exposed for prolonged periods (not quantified) to
18.6 mg/m3 ammonium chloroplatinate (IV). At an exposure level of 4.5 mg/m3 the effects
were reported to be slight and reversible.
Hyperreactivity in respiratory passages, expressed as significant changes in some lung
function parameters, is reported in a study in which monkeys were exposed to 216 m g/m3
sodium hexachloroplatinate (IV) 4 hours/day, 2 days/week for 12 weeks, and 2 weeks later
exposed to a provocation dose of platinum salts (aerosol). The provocation produced no
indications of bronchial hyperreactivity at a dose level of 1940 m g/m3 or when the platinum
salt had been applied repeatedly to the skin for 12 weeks. According to the authors, the
amount of platinum salts the monkeys had been exposed to at an air concentration of 200
m g/m3 was three to four times the amount that a worker is exposed to in a week at an
exposure level of 2 m g/m3. The results indicated a pharmacological or irritant-mediated
mechanism for bronchial constriction with acute exposure, since bronchial provocation
with sodium hexachloroplatinate (IV) revealed some deterioration of lung function in
animals in all groups (significant in controls at the highest dose) (11). A later study with
monkeys reports that exposure to 177 m g/m3 ammonium hexachloroplatinate (IV) 6
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hours/day, 5 days/week for 12 weeks had no significant effect (average value) on reactivity
to platinum salts or methacholine (compared with reactivity to these substances in
provocation tests given before the exposures), whereas the provocation results after
exposure to 208 m g/m3 ammonium hexachloroplatinate (IV) combined with 1 ppm ozone
indicated an increase of both specific and non-specific bronchial hyperreactivity. The
combined exposure also increased the incidence of positive reactions to skin tests with Pt
(intracutaneous injections) (10).
Immunological reactions have been observed in experimental animals after administration
of platinum salts. In one study with mice, administration of sodium hexachloroplatinate
(IV), ammonium hexachloroplatinate (IV), or sodium tetrachloroplatinate (II) yielded a
dose-dependent lymph node activation, and it was observed that only about a fifth of the
original dose was needed to trigger a secondary reaction (71). Ammonium
tetrachloroplatinate (II) was classified as extremely sensitizing when tested in the guinea pig
maximization test (5).
Some platinum salts have been tested on rabbits for irritation of skin and eyes. Among
the compounds reported to cause moderate to severe skin irritation are ammonium
tetrachloroplatinate (II), sodium hexahydroxyplatinate (IV), and tetraammine platinum (II)
chloride. Sodium hexachloroplatinate (IV) and potassium tetrachloroplatinate (II) were
reported to cause eye irritation, and tetraammine platinum (II) chloride, diammine
dinitroplatinum (II) and ammonium tetrachloroplatinate (II) were strongly irritating or
corrosive when applied to eyes (28, 35).
Mutagenicity, carcinogenicity
Numerous platinum compounds have been tested in various in vitro test systems, and many
of them have been found to be genotoxic/mutagenic (46). In tests with Salmonella
typhimurium (usually without metabolic activation), mutagenic activity has been shown for
hexachloroplatinic (IV) acid, platinum (IV) chloride, ammonium hexachloroplatinate (IV),
potassium tetrachloroplatinate (II), cis-potassium dichlorodinitroplatinate (II), ammonium
ammine trichloroplatinate (II), potassium ammine trichloroplatinate (II), chlorotriammine
platinum (II) chloride, and tetraammine platinum (II) chloride (28, 38, 42, 63, 82). In one
study, positive results were reported for platinum (IV) chloride, hexachloroplatinic (IV)
acid, and ammonium hexachloroplatinate (IV) in tests with E. coli and/or Bacillus subtilis
(38). Various types of genotoxicity (DNA inhibition, chromosomal malsegregation) have
also been reported in yeast in a few tests with platinum (IV) chloride and potassium
tetrachloroplatinate (II) (24, 76). Tests on mammalian cells in vitro (without addition of
metabolic systems) have shown mutagenic activity for platinum (IV) chloride, platinum
(IV) sulfate, potassium tetrachloroplatinate (II), potassium hexachloroplatinate (IV),
potassium ammine itrichloroplatinate (II) and chlorotriammine platinum (II) chloride (18,
29, 36, 39, 68, 75, 78, 79, 80, 81). Mutagenic effects were also reported in a study of
fruit flies (in vivo) after oral administration of a solution of platinum (IV) chloride (89).
No relevant cancer studies of platinum compounds used in industry were found in the
literataure. The cancer drug cisplatin and a few other cis-platinum (II) coordination
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complexes with tumor-inhibiting effects have been shown to be carcinogenic to
experimental animals (33, 34, 43).
Reproduction toxicity
No notable effects on fetuses (fetus weight, number of resorptions, number of fetuses with
developmental aberrations) or placenta (weight) were reported in a study (12) in which rats
were given metallic platinum or platinum (IV) chloride in feed before and during gestation
(up to 100 mg Pt/kg feed; total 7 weeks). Nor were effects observed on young (weight,
hematological parameters) of rats given platinum (IV) chloride or platinum (II) chloride in
feed (up to 100 mg Pt/kg feed) during lactation (41). Effects on young were also
investigated in a study in which mice were given a dose of platinum (IV) sulfate (200 mg
Pt/kg body weight, per os) or sodium hexachloroplatinate (IV) hexahydrate (20 mg Pt/kg,
subcutaneous) during gestation or lactation (19). Administration of platinum (IV) sulfate
during gestation resulted in reduced body weight in young (up to day 45 after birth), but it
could be shown that pups of unexposed mothers who were cared for by platinum -exposed
mothers also had reduced body weight. When platinum (IV) sulfate was given to the
mothers during lactation (day 2), the pups were reported to be less active than normal.
Administration of sodium hexachloroplatinate (IV) on day 12 of gestation resulted in
reduced activity in pups.
Injection of platinum (IV) chloride into the testes of male rats is reported to cause
necrosis and reduced testes weight. When the substance was injected in lower doses (total
dose 27 mg/kg b.w.) under the skin of mice for 30 days, it resulted in lower testes weights
and inhibited spermatogenesis (37).
Dose-effect / dose-response relationships
The only reported effects of occupational exposure to soluble platinum salts are allergy and
irritation. There are no data at all on the effects of human exposure to metallic platinum and
insoluble platinum salts. Reliable measures of air concentrations are sparse, and it is
therefore difficult to determine an exposure level at which allergy might be induced. In one
study (4), however, it is reported that sensitization to platinum salts (expressed as a
positive prick test) could be shown in 2 of 3 workers (67%) in a part of a refinery where
the average concentration was 27.1 m g/m3, in 2 of 14 workers (14%) where the average
concentration was 10.7 m g/m3, and in 2 of 19 workers (11% ) where the average
concentration was 0.4 m g/m3 and reportedly did not exceed 2.0 m g/m3 on any monitoring
occasion. There are also indications that persons previously sensitized to platinum salts can
develop symptoms of respiratory allergy at air concentrations below 2 m g/m3 – possibly as
low as 0.08 – 0.1 m g/m3 (15, 55, 56).
Effects on kidneys, thymus and testes have been observed in animals exposed to soluble
platinum salts. The exposure-effect relationships observed in animal experiments are
summarized in Table I.
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Table 1. Exposure-effect relationships observed in experimental animals given soluble
platinum salts.
________________________________________________________________________
























Mouse Reduced testes wight,
inhibited spermatogenesis
37
Pt(SO4)2x4H20 750 mg/L in
drinking water,
8 days ( » 140
mg/kg/day)
Rat Lower weight gain, reduced
aniline hydroxylase activity
26, 27
PtCl4 550 mg/L in
drinking water,
29 days ( » 74
mg/kg/day)
Rat Lower weight gain,
higher relative kidney weight
26










The critical effect of occupational exposure to soluble platinum salts is effects on the
respiratory passages. It has been shown that smokers have an elevated risk of sensitization
to platinum salts. Metallic platinum has not been associated with respiratory effects. There
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This report is based primarily on a criteria document produced by the Nordic Expert Group
(44).






Boiling point: 130.5 ° C
Melting point: - 68.7 ° C
Vapor pressure: 0.66 kPa (20 ° C)
Saturation concentration in air: 0.65% (20 ° C) (= 45.3 mg/m3 )
Conversion factors: 1 ppm = 6.96 mg/m3 (20 ° C)
1 mg/m3 = 0.144 ppm (20 ° C)
1,1,2,2-Tetrachloroethane
CAS No: 79-34-5




Boiling point: 146.5 ° C
Melting point: - 42.5 ° C
Vapor pressure: 0.68 kPa (20 ° C)
Saturation concentration in air: 0.67% (20 ° C) (= 46.7 mg/m3 )
Solubility in water: 0.3% (20 ° C)
Conversion factors: 1 ppm = 6.96 mg/m3 (20 ° C)
1 mg/m3 = 0.144 ppm (20 ° C)
Tetrachloroethane (TCE) occurs in two isomeric forms: 1,1,1,2-tetrachloroethane (1,1,1,2-
TCE) and 1,1,2,2-tetrachloroethane (1,1,2,2-TCE). Both isomers are heavy, colorless,
non-flammable liquids (36, 78). Contact with hot metal or open flame may result in
formation of poisonous phosgene gas (36). TCE is soluble in several organic solvents –
ethanol, diethyl ether, benzene, chloroform, etc.– but its solubility in water is extremely
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low (4, 44, 78). 1,1,2,2-TCE has a sweet smell (36, 73) and in one work (1) the average
odor threshold is reported to be 10 mg/m3 (1.5 ppm). Another work (40) reports that the
odor is recognizable at 20 mg/m3 and that the sense of smell is deadened at high
concentrations.
1,1,1,2-TCE is not produced on an industrial scale, but frequently occurs as a by-
product in chlorination of C2 hydrocarbons (78), and is found as a contaminant in e.g.
trichloroethylene and tetrachloroethylene (8). 1,1,2,2-TCE was once widely used as an
intermediate in the production of other chlorinated hydrocarbons, and also had widespread
use as a solvent. The substance was used in a wide variety of industries, ranging from
synthetic fibers, electronics and pesticides to production of artificial pearls. It had a special
use in the aviation industry: to impregnate the varnish on airplane wings (3, 4, 56, 60, 73).
The use of 1,1,2,2-TCE has been cut back considerably in recent decades, and it now
occurs primarily as an unisolated intermediate in the production of trichloroethylene.
Manufacture of 1,1,2,2-TCE as an end product is reported to be extremely limited.
However, 1,1,2,2-TCE may sometimes be isolated and used in production of
trichloroethylene, tetrachloroethylene and 1,2-dichloroethylene. It is possible that minor
amounts of 1,1,2,2-TCE are also used as solvents and pesticides (44, 67). Neither
1,1,2,2-TCE nor 1,1,1,2-TCE may be present in concentrations exceeding 0.1% by weight
in chemicals or products sold to the public (44).
Uptake, biotransformation, excretion
TCE can be absorbed via both lungs and digestive tract (see toxicity data), but quantitative
data are sparse. In one study (51) it is reported that when a subject inhaled a vapor of 38Cl-
labeled 1,1,2,2-TCE (one breath), 3.3% of the absorbed dose was exhaled within an hour.
In another study, in which rats were exposed to 2450 mg/m3 (352 ppm) 1,1,1,2-TCE or
2440 mg/m3 (350 ppm) 1,1,2,2-TCE for 6 hours, there were indications of considerable
uptake via lungs (21). There is virtually no information on skin uptake, but data from the
EPA on the permeability of human skin (permeability coefficient) indicate that 1,1,2,2-TCE
has limited ability to penetrate skin (44, 79). However, extensive skin contact can lead to a
significant uptake: according to a calculation in Reference 44, about 10.8 mg/hour via
contact with the palms of both hands (about 400 cm2).
Both 1,1,1,2-TCE and 1,1,2,2-TCE are metabolized to a great extent. In a study with
mice, within 4 hours after an intravenous injection of 14C-1,1,2,2-TCE in the mucous
membranes of the respiratory passages and upper alimentary tract, the highest
concentrations of radioactivity were found in liver, gall bladder, adrenal cortex and testes
(interstitial tissue), and it could be established that a large portion of the radioactivity was
irreversibly bound in metabolites (17).
Biotransformation of 1,1,1,2-TCE involves both oxidative and reductive metabolism (8).
In an inhalation study in which rats were exposed to 2450 mg/m3 (352 ppm) for 6 hours,
the maximum metabolism rate (Vmax) was determined to be 6.39 mg/kg/hour (21).
Excretion of trichloro compounds (trichloroacetic acid, trichloroethanol) in urine has been
demonstrated in several studies (33, 43, 50). In one study (33) with rats, the amount of
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trichlorinated compounds in urine (mostly trichloroethanol) is reported to be more than 20
times greater after exposure to 1,1,1,2-TCE than after exposure to 1,1,2,2-TCE; another
study (50) with mice and rats reports that trichloroethanol/trichloroacetic acid was the
principal metabolite for both isomers. Reductive metabolism of 1,1,1,2-TCE has been
demonstrated in several studies (71, 74) and significant quantities of 1,1-dichloroethylene
have been identified in vivo (rat blood) as well as in vitro after administration of 1,1,1,2-
TCE (71). In a comparative in vitro study (rat liver microsomes) it is reported that under
anaerobic conditions 1,1,1,2-TCE was reduced much more rapidly than 1,1,2,2-TCE (71).
1,1,2,2-TCE is metabolized mostly by oxidative metabolism. In an inhalation study in
which rats were exposed for 6 hours to 2440 mg/m3 (350 ppm) 1,1,2,2-TCE, the
maximum metabolism rate (Vmax) was determined to be 12.9 mg/kg/hour (21). One of the
primary metabolic pathways involves incremental hydrolytic splitting of the carbon-chlorine
bond via dichloroacetic acid (urine metabolite) to glyoxylic acid (urine metabolite) and
subsequent transformation, notably to carbon dioxide. In vitro studies have indicated an
alternative metabolic pathway via dichloroacetyl chloride (reactive metabolite) instead of
dichloroacetaldehyde for transformation of 1,1,2,2-TCE to dichloroacetic acid (7, 9, 24,
60). 1,1,2,2-TCE can also undergo elimination of hydrogen chloride and form
trichloroethylene, which then yields the urine metabolites trichloroacetic acid and
trichloroethanol (8, 33, 50). Small amounts of tetrachloroethylene (trichloroacetic acid and
oxalic acid in later steps) can also be formed with oxidation of 1,1,2,2-TCE (85).
Reductive dechlorination and formation of free radicals have been indicated in some studies
with 1,1,2,2-TCE and the metabolites dichloroacetic acid and trichloroacetic acid (37, 60,
72).
Both 1,1,1,2-TCE and 1,1,2,2-TCE are excreted mostly as metabolites. In a study (85)
in which mice were given intraperitoneal injections of 14C-1,1,2,2-TCE, it is reported that
about three fourths of the dose was excreted within 48 hours, most of it as metabolites
during the first 24 hours. In another study with mice and rats (50), it was shown that about
half of an oral dose of 14-C labeled 1,1,2,2-TCE and about 90% of a dose of 14C-1,1,1,2-
TCE were excreted within 48 hours, mostly as metabolites. A calculation based on
perfusion rate, tissue volume and distribution coefficient (oil/blood) indicates that 1,1,2,2-
TCE accumulates in human fat to some extent but is eliminated fairly quickly, with a half
time of about 34 hours (44).
Toxic effects
Animal data
With inhalation and oral administration, 1,1,1,2-TCE has higher LC50 and LD50 values than
1,1,2,2-TCE. The LD50 for rats has been reported to be 670 mg/kg for the first substance
and 250 mg/kg for the second. The reported LC50 for rats (4 hours) is 14,600 mg/m3 (2100
ppm) for the first substance, and 8600 mg/ m3 for the second (44, 64). The lowest reported
LC50 (mice, 2 hours) for 1,1,2,2-TCE is 4500 mg/m3 (44). With dermal application to
rabbits, an LD50 of 20 g/kg has been reported for 1,1,1,2-TCE (44).
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With short-term exposure to high concentrations of TCE in air, the toxic picture is
distinguished mostly by CNS symptoms (38, 39, 52, 59). The anesthetic qualities of
tetrachloroethane have been demonstrated, for example, in a study with cats (39), in which
exposure to 5700 mg/m3 1,1,2,2-TCE resulted in slight narcosis after a bit over 4 hours.
CNS effects were also reported in cats that had been exposed to an average 1400 mg/m3 6
to 7 hours/day for 4 weeks (18 exposures) (39).
Damage to liver (e.g. fatty degeneration), kidneys, intestinal mucosa, eyes etc. has been
observed in animal experiments with single or brief exposures to TCE in high
concentrations (18, 26, 29, 44, 52). Short-term exposures to low air concentrations are
reported to affect primarily the liver. In one study, rats were exposed for 4 hours to
1,1,2,2-TCE in concentrations ranging from 410 to 4200 mg/m3, and diffuse fatty
degeneration was noted even at the lowest dose (64). Another inhalation experiment with
rats (14, 44) reports an increase of aminotransferases (ASAT, ALAT) in serum 24 hours
after a 6-hour exposure to 1,1,2,2-TCE in air concentrations of 70 and 690 mg/m3 (10 and
100 ppm), although histopathological examination revealed no clear changes in liver.
However, histopathological changes in liver were reported in another experiment in which
rats were repeatedly exposed to 15 mg/m3 1,1,2,2-TCE for 10 days (23, 62).
Prolonged exposure of rabbits (6 months) and rats (12 months) to 3430 mg/m3 (500
ppm) 1,1,1,2-TCE was reported to cause liver damage in the form of centrilobular necroses
and microvacuolization (30, 76). Exposure to 3900 mg/m3 (560 ppm) 1,1,2,2-TCE for 15
weeks also caused liver changes in rats (44, 75). No effects on kidneys, lungs, adrenals,
ovaries or uterus were observed in histopathological examination. In a study designed to
discover glomerulopathy in rats, small changes in glomeruli were noted after exposure to
3600 mg/m3 (516 ppm) 1,1,2,2-TCE for 13 weeks (13, 44). A long-term experiment in
which rats were exposed to 13.3 mg/m3 1,1,2,2-TCE for 9 months resulted in reduced
ACTH level in pituitaries (the change was greatest on the first examination, i.e. after 4
months of exposure), and minor, transient changes in liver lipids, body weight etc. (62).
In a long-term study, one monkey was given a fluctuating exposure ranging from 6960
to 27,800 mg/m3 (1000 – 4000 ppm) unspecified TCE for a total of 190 2-hour sessions
over a period of 9 months; it developed diarrhea and loss of appetite (anorexia) after the
12th exposure and became nearly unconscious (for 20 to 60 minutes) starting with the 15th
exposure. Hemoglobin levels and erythrocyte counts dropped 3 – 4 months after the
exposures were begun, but this was followed by an increase. The histopathological
examination revealed centrilobular fatty degeneration and vacuolization in the liver. No
exposure-related effects were seen on heart, lungs, kidneys, pancreas or testes (29).
With oral administration of 1,1,1,2-TCE to mice (250 mg/kg/day, 5 days/week for 103
weeks, or 500 mg/kg/day, 5 days/week for 65 weeks) and rats (125 or 250 mg/kg/day, 5
days/week for 103 weeks), CNS toxicity and liver damage were observed in mice in the
high-dose group, and CNS toxicity in rats in the high-dose group (30, 58). Other studies
with oral administration (doses of 300 to 500 mg/kg) of 1,1,1,2-TCE to rats, guinea pigs
and rabbits for various lengths of time also report indications of liver damage (30).
Oral administration of 1,1,2,2-TCE to mice (0, 100 – 200 or 200 – 400 mg/kg/day, 5
days/week for 78 weeks) resulted in a dose-related increase in mortality. Many deaths
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among males in the high-dose group (week 69 – 70) were due to acute tubular nephrosis
(53). There was also an increase of early deaths among females in the high-dose group.
The same study also reports a dose-related negative effect on growth in rats given 40 – 65
mg/kg/day or 80 – 130 mg/kg/day 1,1,2,2-TCE for up to 78 weeks. In another study
(mice), intraperitoneal injections of 1,1,2,2-TCE, 300 or 600 mg/kg, resulted in
biochemical effects in liver, and females in the high-dose group had reduced liver weights
(60).
To clarify the acute neurochemical effects of 1,1,2,2-TCE, the concentration of
neurotransmitters and metabolites in various parts of the brains of male rats were measured
after oral doses of 1,1,2,2-TCE (50 mg/kg). It was found that the levels of the serotonin
metabolite 5-hydroxyindole acetic acid (mesencephalon), dopamine (medulla oblongata)
and serotonin (medulla oblongata) rose significantly (35).
1,1,2,2-TCE is reported to be strongly irritating to skin and mucous membranes (36).
Human data
There are several reported deaths due to oral intake of unknown quantities of 1,1,2,2-TCE.
These cases are characterized by effects on the central nervous system, including loss of
consciousness, and death occurred within 12 hours (16, 19, 41, 45). Temporary loss of
consciousness has been reported after oral intake of 3 ml (about 60 – 80 mg/kg body
weight) 1,1,2,2-TCE (65).
Many cases of poisoning have also occurred during work with 1,1,2,2-TCE, especially
in the European aircraft industry in the early 1900s. In some cases the primary symptoms
of poisoning involved the digestive tract. Jaundice and enlarged livers were observed, and
in fatal cases severe liver damage was found at autopsy (19, 27). In other cases, there were
neurological symptoms in addition to nausea and loss of appetite (27). Changes in
hematological parameters, including increase of large mononuclear cells, have sometimes
been observed to precede the clinical symptoms of poisoning (48).
There are a few studies in which both the symptoms of exposed persons and the air
concentrations of TCE are reported. In one study, two volunteers were exposed to 1,1,2,2-
TCE in concentrations of 20 to 2300 mg/m3 for periods of up to 30 minutes. Exposure to
20 – 90 mg/m3 for 10 minutes was reported to have no noteworthy effects. With exposure
to 800 mg/m3 it was observed that the odor was no longer discernible after 10 minutes, and
slight nausea was felt at the end of the 20-minute exposure. Exposure to 1000 mg/m3
resulted in dizziness after 10 minutes, irritated mucous membranes after 12 minutes and
drowsiness after 20 minutes. At an air concentration of 1800 mg/m3 the subjects became
dizzy after only 5 minutes, and the exposure (10 minutes) also resulted in irritation of
mucous membranes in eyes, nose and mouth (40).
In a Hungarian study (34, 44) it is reported that about half of the workers in a penicillin
factory had indications of poisoning, including digestive disorders, headaches and weight
loss. Many of these workers also had enlarged livers and abnormal results on tests of liver
function. The concentration of 1,1,2,2-TCE in different processes ranged from 10 to 1700
mg/m3 (1.5 to 247 ppm). The health of the workers improved when the work environment
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was improved, and most of them were reported to be free of symptoms when the maximum
air concentration of 1,1,2,2-TCE was 250 mg/m3 (36 ppm).
A Japanese study (28) reports air concentrations of TCE ranging from 490 to 1560
mg/m3 (70 to 224 ppm) in three factories where artificial pearls were produced. Medical
examination of 18 workers revealed deviations from normal results in many of them:
neurological symptoms, low erythrocyte counts and/or relative lymphocytosis, etc. After
the air concentration of TCE was reduced to 0 – 140 mg/m3 (20 ppm) it was observed that
the proportion of workers with abnormal test results (blood) declined substantially.
In a study of 380 workers in 23 factories in India where 1,1,2,2-TCE was used as a
solvent for cellulose acetate, it is reported that symptoms of poisoning appeared after about
3 months of exposure. Air concentrations (average) were determined to be 63 to 680
mg/m3 (9 to 98 ppm), but frequent skin contact with the substance in liquid form was also
common. Among the most exposed persons, CNS symptoms (e.g. finger tremor,
headache, dizziness) were most common, but symptoms involving the digestive system
(loss of appetite, nausea, vomiting, stomach cramps) were also widespread. Enlarged
livers or jaundice were not seen. There appeared to be a dose-response relationship for
tremor, but the importance of e.g. skin exposure to 1,1,2,2-TCE can not be assessed (42).
In an Italian study (22, 44), 75 persons exposed to TCE were examined for effects on
heart and circulatory system. No significant differences from normal values were observed
in clinical examinations (including pulse, ECG). Air concentrations (average values)
around production of TCE were reported to range from 2.6 mg/m3 to 9.3 mg/m3, but a
peak of 22 mg/m3 was also measured. In other occupational contexts (including laboratory
work and production of trichloroethylene and tetrachloroethylene), concentrations of TCE
ranged from 35 to 104 mg/m3 with occasional peaks of 278 mg/m3.
In a retrospective cohort study (1946 – 1976) of 1,099 men who were exposed to
1,1,2,2-TCE for brief periods (5 weeks to 1 year), there was no significant increase in
mortality due to heart/circulatory diseases. Nor was there a significant increase of total
mortality, or deaths due to cancer or liver cirrhosis. No exposure data are given in this
study (57).
Mutagenicity
1,1,1,2-TCE has yielded negative results in most studies with bacteria, yeast or moulds
(25, 46, 47, 61, 81, 82), but mutagenic/genotoxic effects were observed in a study with
Salmonella typhimurium and in a study with Aspergillus nidulans (12, 67). In tests on
mammalian cells in vitro, 1,1,1,2-TCE has caused sister chromatid exchanges and
mutations, but negative results were obtained in other tests of DNA repair, cell
transformation or chromosome aberrations (20, 47, 68, 69, 77, 83). A study with
Drosophila, in which genetic damage in somatic cells was examined after inhalation
exposure of larvae (1000 ppm) also yielded negative results (80).
1,1,2,2-TCE has also been tested in several in vitro test systems. Most studies with
Salmonella typhimurium have yielded negative results (25, 47, 55, 61, 81), but in some
studies 1,1,2,2-TCE has been reported to be mutagenic (2,46, 67). In genotoxicity tests
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with yeasts/moulds, positive results were obtained in two of three studies (6, 12, 54).
DNA damage has also been indicated in some tests with E. coli (2, 15). In tests with
mammalian cells in vitro, sister chromatid exchange (10, 20) and cell transformation (two
studies) have been observed (10, 11, 47, 77), but DNA repair and chromosome aberrations
have not been reported (20, 47, 83). A few in vivo studies were also found. In one study
with mice, no increase of DNA repair synthesis or DNA replication synthesis was observed
in hepatic cells (with equivocal result regarding S-phase synthesis in females) after oral
administration of 50 – 1000 mg/kg or 200 – 700 mg/kg 1,1,2,2-TCE (49). In a gene
mutation test with Drosophila (sex-linked recessive lethals) it was concluded that 1,1,2,2-
TCE was not mutagenic after injection of 800 ppm or oral administration of 1500 ppm
(84). Monitoring of genetic damage in somatic cells after inhalation exposure (500 ppm) of
larvae also yielded negative results (80).
On the basis of the covalent bonding index for hepatic DNA (in vivo: mice, rats),
1,1,1,2-TCE has been classified as a weak to moderate initiator of genotoxic activity and
1,1,2,2-TCE as a moderate initiator of genotoxic activity (8, 9).
Carcinogenicity
In a cancer study, mice were given 1,1,1,2-TCE by gavage 5 days/week, 250 mg/kg/day
for 103 weeks or 500 mg/kg/day for 65 weeks (all the animals in the high-dose group died
or were killed after 65 weeks). A significant, dose-related increase in the incidence of
hepatocellular adenomas was observed in both males (controls 6/48; low-dose 14/46; high-
dose 21/50) and females (4/49, 8/46, 24/48), and a dose-related increase of hepatocellular
carcinomas (p ‹ 0.05) was observed in females (1/49, 5/46, 6/48). Rats were given
1,1,1,2-TCE by gavage, 125 or 250 mg/kg/day, 5 days/week for 103 weeks: there was a
statistically significant increase in the incidence of fibroadenomas in mammary glands of
females in the low-dose group, but not in the high-dose group (6/49, 15/49, 7/46) (30).
One study (53) with oral administration of 1,1,2,2-TCE to mice (100 – 200 or 200 – 400
mg/kg/day, 5 days/week for up to 78 weeks) reports a significant, dose-related increase of
hepatocellular carcinomas in both males and females. Liver carcinomas were observed in
2/19 untreated controls, 1/18 vehicle controls, 13/50 males in the low-dose group, and
44/49 males in the high-dose group. The corresponding figures for females were 0/19,
0/20, 30/48, and43/47. Rats given 1,1,2,2-TCE by gavage (80 – 130 mg/kg/day or 40 –
65 mg/kg/day, 5 days/week for up to 78 weeks) showed no significant increase in
incidence of any tumor type. Two of 49 males in the high-dose group, however, developed
liver carcinomas, and one other animal in this group had neoplastic changes (nodules) in
the liver (53). In a 24-week study (70), mice were given intraperitoneal injections of 80,
200 or 400 mg/kg 1,1,2,2-TCE 3 times/week (total 5, 18 or 16 injections) and examined
for the occurrence of lung adenomas. The highest dose resulted in a slightly elevated
incidence of lung tumors (not statisticallly significant), but by the end of the study most of
the animals in this dose group had died.
In an initiation-promotion study (47, 66), rats were given oral doses of 200 mg/kg
1,1,1,2-TCE or 100 mg/kg 1,1,2,2-TCE, as initiator or as promotor (5 days/week for 7
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weeks); 1,1,2,2-TCE (but not 1,1,1,2-TCE) induced an increase of GGT+ (gamma-
glutamyl transferase) foci in liver. 1,1,2,2-TCE administered in accordance with the
promotion protocol induced a significant increase of GGT+ foci both with and without the
use of known initiators. The results indicate that 1,1,2,2-TCE is a complete carcinogen,
with a slight ability to function as initiator and a strong ability to function as promotor.
In the judgement of the IARC, there is ”limited evidence” that 1,1,1,2-TCE and 1,1,2,2-
TCE are carcinogenic to experimetal animals, but it is not possible to determine whether
either substance is carcinogenic to humans (31). In the overall IARC assessment, both
substances are placed in Group 3: ”not classifiable as to its carcinogenicity to humans”
(31). It should be observed that the TCE metabolites trichloroethylene, tetrachloroethylene,
dichloroacetic acid and trichloroacetic acid have been shown to be carcinogenic in animal
experiments (32). The two latter metabolites have been shown to induce liver tumors in
mice (5, 32). The overall assessments of the IARC for trichloroethyene and
tetrachloroethylene are that these substancess are ”probably carcinogenic to humans”
(Group 2A) (32). The overall assessments of the IARC for dichloroacetic acid and
trichloroacetic acid are that these substances are ”not classifiable as to its carcinogenicity to
humans” (Group 3) (32).
Reproduction toxicity
In an incompletely reported study with rats (30, 76), it is stated that pups born to mothers
exposed to 1,1,1,2-TCE either orally or by inhalation (dose not reported) died within two
days of birth. No other reproductive disturbances were reported. Another study reports that
1,1,2,2-TCE was embryotoxic to mice with intraperitoneal injection during gestation (63).
An increased number of post-implantation losses was observed in one strain of mice (700
mg/kg on day 9 or 400 mg/kg/day on days 7-14), and an increase in the number of non-
pregnant females was reported in another strain of mice (300 mg/kg/day, days 1 – 14). A
slight increase in the number of fetuses with aberrations (both strains) was also noted (63).
When male rats were exposed to 13.3 mg/m3 1,1,2,2-TCE for 9 months and then mated
with untreated females, there were no effects on litter size, birth weight, sex distribution,
growth or neonatal mortality. Nor did the young show any deformities (62).
Dose-effect / dose-response relationships
There are very little data on human exposure that can be used as a basis for establishing a
dose-effect or dose-response relationship for either 1,1,1,2-TCE or 1,1,2,2-TCE. The
effects of acute inhalation exposure on human subjects are summarized in Table 1.
The dose-effect relationships observed in animal experiments are summarized in Table 2.
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1800 mg/m3 (259 ppm)
5 – 10 minutes
Dizziness, irritation of mucous membranes
1000 mg/m3 (144 ppm)
10 – 20 minutes
Dizziness, irritation of mucous membranes,
fatigue
800 mg/m3 (115 ppm)
20 minutes
Slight nausea




Table 2. Exposure-effect relationships observed in laboratory animals with inhalation
exposure to 1,1,2,2-TCE.
________________________________________________________________________







Monkey CNS effects, diarrhea, loss of





5700 mg/m3 4 hrs 15
minutes
Cat Slight narcosis 39
3900 mg/m3 5 – 6 hrs/day,
5 days/week,
15 weeks
Rat Increased relative liver weights,
indications of liver hyperplasia,
granulation and vacuolization




1400 mg/m3 6 – 7 hrs/day,
18 sessions
Cat CNS effects 39
410 mg/m3 4 hrs Rat Diffuse fatty degeneration in
liver
64
70 mg/m3 6 hrs Rat Increases in ASAT, ALAT 14,
44
15 mg/m3 4 hrs/day,
4 or 8 sessions
in 10 days
Rat Slight inflammatory changes,
including small necrotic foci and
fat accumulation in liver
23,
62
13.3 mg/m3 4 hrs/day,
9 months
Rat Reduced ACTH in pituitary,
minor, temporary changes
including liver lipid content
(increase at 9 months) and body





Occupational exposure to 1,1,2,2-TCE has effects on liver, digestive tract and central
nervous system, but data on human exposure provide an insufficent basis for establishing a
critical effect. Judging from animal experiments, the critical effect of exposure to 1,1,1,2-
TCE and 1,1,2,2-TCE is cancer. Liver tumors have been observed in mice after oral
administration of both substances, but the mechanism behind the TCE-induced liver
carcinogenesis is not clear. Both isomers can bind to DNA and have shown some
mutagenic/genotoxic activity in vitro. TCE can penetrate the skin.
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Dimethylether September 14, 1994 1995:19 (XVI)
Dimethylethylamine June 12, 1991 1992:6 (XII)
Dimethylformamide March 23, 1983 1983:36 (IV)
Dimethylhydrazine January 27, 1993 1993:37 (XIV)
Dimethylsulfide September 9, 1986 1987:39 (VIII)
Dimethylsulfoxide, DMSO December 11, 1991 1992:47 (XIII)
Dioxane August 25, 1982 1983:36 (IV)
revised March 4, 1992 1992:47 (XIII)
Diphenylamine January 25, 1995 1995:19 (XVI)
4,4'-Diphenylmethanediisocyanate April 8, 1981 1982:9 (II)
Dipropylene glycol May 26, 1993 1993:37 (XIV)
Dipropyleneglycol monomethylether December 12, 1990 1992:6 (XII)
Disulfiram October 31, 1989 1991:8 (XI)
Enzymes, industrial June 5, 1996 1996:25 (XVII)
Ethanol May 30, 1990 1991:8 (XI)
Ethanolamine September 4, 1991 1992:47 (XIII)
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Ethylacetate March 28, 1990 1991:8 (XI)
Ethylamine August 25, 1982 1983:36 (IV)
Ethylamylketone September 5, 1990 1992:6 (XII)
Ethylbenzene December 16, 1986 1987:39 (VIII)
Ethylchloride December 11, 1991 1992:47 (XIII)
Ethylene chloride February 29, 1980 1981:21 (I)
Ethylene diamine August 25, 1982 1983:36 (IV)
Ethylene glycol October 21, 1981 1982:24 (III)
Ethyleneglycol monoisopropylether November 16, 1994 1995:19 (XVI)
Ethyleneglycol monopropylether + acetate September 15, 1993 1994:30 (XV)
Ethylene oxide December 9, 1981 1982:24 (III)
Ethylether January 27, 1993 1993:37 (XIV)
Ethylglycol October 6, 1982 1983:36 (IV)
Ferbam September 12, 1989 1991:8 (XI)
Ferric dimethyldithiocarbamate September 12, 1989 1991:8 (XI)
Formaldehyde June 30, 1979 1981:21 (I)
revised August 25, 1982 1983:36 (IV)
Formamide December 12, 1989 1991:8 (XI)
Formic acid June 15, 1988 1988:32 (IX)
Furfural April 25, 1984 1984:44 (V)
Furfuryl alcohol February 13, 1985 1985:32 (VI)
Gallium + Gallium compounds January 25, 1995 1995:19 (XVI)
Glycol ethers October 6, 1982 1983:36 (IV)
Glyoxal September 13, 1996 1996:25 (XVII)
Grain dust December 14, 1988 1989:32 (X)
Halothane April 25, 1985 1985:32 (VI)
2-Heptanone September 5, 1990 1992:6 (XII)
3-Heptanone September 5, 1990 1992:6 (XII)
Hexachloroethane September 15, 1993 1994:30 (XV)
Hexamethylenediisocyanate April 8, 1981 1982:9 (II)
Hexamethylenetetramine August 25, 1982 1983:36 (IV)
n-Hexane January 27, 1982 1982:24 (III)
2-Hexanone September 5, 1990 1992:6 (XII)
Hexyleneglycol November 17, 1993 1994:30 (XV)
Hydrazine May 13, 1992 1992:47 (XIII)
Hydrogen fluoride April 25, 1984 1984:44 (V)
Hydrogen peroxide April 4, 1989 1989:32 (X)
Hydrogen sulfide May 4, 1983 1983:36 (IV)
Hydroquinone October 21, 1989 1991:8 (XI)
Indium March 23, 1994 1994:30 (XV)
Industrial enzymes June 5, 1996 1996:25 (XVII)
Isophorone February 20, 1991 1992:6 (XII)
Isopropanol December 9, 1981 1982:24 (III)
Isopropylamine February 7, 1990 1991:8 (XI)
Isopropylbenzene June 2, 1982 1982:24 (III)
Lactates March 29, 1995 1995:19 (XVI)
Lead, inorganic February 29, 1980 1981:21 (I)
revised September 5, 1990 1992:6 (XII)
Lithium boron nitride January 27, 1993 1993:37 (XIV)
Lithium nitride January 27, 1993 1993:37 (XIV)
Maleic anhydride September 12, 1989 1991:8 (XI)
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Manganese February 15, 1983 1983:36 (IV)
revised April 17, 1991 1992:6 (XII)
Man made mineral fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Mercury, inorganic April 25, 1984 1984:44 (V)
Mesityl oxide May 4, 1983 1983:36 (IV)
Metal stearates, some September 15, 1993 1994:30 (XV)
Methacrylates September 12, 1984 1985:32 (VI)
Methanol April 25, 1985 1985:32 (VI)
Methyl acetate March 28 1990 1991:8 (XI)
Methylamine August 25, 1982 1983:36 (IV)
Methylamyl alcohol March 17, 1993 1993:37 (XIV)
Methyl bromide April 27, 1988 1988:32 (IX)
Methyl chloride March 4, 1992 1992:47 (XIII)
Methyl chloroform March 4, 1981 1982:9 (II)
Methylene chloride February 29, 1980 1981:21 (I)
4,4'-Methylene dianiline June 16, 1987 1987:39 (VIII)
Methyl ethyl ketone February 13, 1985 1985:32 (VI)
Methyl ethyl ketone peroxide February 13, 1985 1985:32 (VI)
Methyl formare December 12, 1989 1991:8 (XI)
Methyl glycol October 6, 1982 1983:36 (IV)
Methyl iodide June 30, 1979 1981:21 (I)
Methylisoamylamine September 5, 1990 1992:6 (XII)
Methyl mercaptane September 9,  1986 1987:39 (VIII)
Methyl methacrylate March 17, 1993 1993:37 (XIV)
Methyl pyrrolidone June 16, 1987 1987:39 (VIII)
Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
Molybdenum October 27, 1982 1983:36 (IV)
Monochloroacetic acid February 20, 1991 1992:6 (XII)
Monochlorobenzene September 16,1993 1993:37 (XIV)
Monomethylhydrazine March 4, 1992 1992:47 (XIII)
Mononitrotoluene February 20, 1991 1992:6 (XII)
Monoterpenes February 17, 1987 1987:39 (VIII)
Morpholine December 8, 1982 1983:36 (IV)
revised June 5, 1996 1996:25 (XVII)
Natural crystallinic fibers (except asbestos) June 12, 1991 1992:6 (XII)
Nickel April 21, 1982 1982:24 (III)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
Nitrosomorpholine December 8, 1982 1983:36 (IV)
Nitrotoluene February 20, 1991 1992:6 (XII)
Nitrous oxide December 9, 1981 1982:24 (III)
Oil mist April 8, 1981 1982:9 (II)
Organic acid anhydrides, some September 12, 1989 1991:8 (XI)
Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
Pentaerythritol November 16, 1994 1995:19 (XVI)
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Peroxides, organic February 13, 1985 1985:32 (VI)
Phenol February 13, 1985 1985:32 (VI)
Phthalates December 8, 1982 1983:36 (IV)
Phthalic anhydride September 12, 1989 1991:8 (XI)
Piperazine September 12, 1984 1985:32 (VI)
Plastic dusts December 16,  1986 1987:39 (VIII)
Polyaromatic hydrocarbons February 15, 1984 1984:44 (V)
Polyisocyanates April 27, 1988 1988:32 (IX)
2-Propanol December 9, 1981 1982:24 (III)
Propene September 13, 1996 1996:25 (XVII)
Propionic acid November 26, 1987 1988:32 (IX)
Propylacetate September 14, 1994 1995:19 (XVI)
Propylene glycol June 6, 1984 1984:44 (V)
Propylene glycol-1,2-dinitrate May 4, 1983 1983:36 (IV)
Propylene glycol monomethylether October 28, 1986 1987:39 (VIII)
Propylene oxide June 11, 1986 1986:35 (VII)
Pyridine May 13, 1992 1992:47 (XIII)
Quartz March 13, 1996 1996:25 (XVII)
Resorcinol September 4, 1991 1992:47 (XIII)
Selenium December 11, 1985 1986:35 (VII)
revised February 22, 1993 1993:37 (XIV)
Silica March 13, 1996 1996:25 (XVII)
Silver October 28, 1986 1987:39 (VIII)
Stearates, metallic, some September 15, 1993 1994:30 (XV)
Stearates, non-metallic, some November 17, 1993 1994:30 (XV)
Strontium January 26, 1994 1994:30 (XV)
Styrene February 29, 1980 1981:21 (I)
revised October 31, 1989 1991:8 (XI)
Sulfur dioxide April 25, 1985 1985:32 (VI)
Sulfur fluorides March 28, 1990 1991:8 (XI)
Synthetic inorganic fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Synthetic organic and inorganic fibers May 30, 1990 1991:8 (XI)
Talc dust June 12, 1991 1992:6 (XII)
Terpenes, mono- February 17, 1987 1987:39 (VIII)
Tetrabromoethane May 30, 1990 1991:8 (XI)
Tetrachloroethylene February 29, 1980 1981:21 (I)
1,1,1,2-Tetrafluoroethane March 29, 1995 1995:19 (XVI)
Tetrahydrofuran October 31, 1989 1991:8 (XI)
Tetranitromethane April 4, 1989 !989:32 (X)
Thioglycolic acid June 1, 1994 1994:30 (XV)
Thiourea December 1, 1987 1988:32 (IX)
Thiram October 31, 1989 1991:8 (XI)
Thiurams, some October 31, 1989 1991:8 (XI)
Titanium dioxide February 21, 1989 1989:32 (X)
Toluene February 29, 1980 1981:21 (I)
Toluene-2,4-diisocyanate April 8, 1981 1982:9 (II)
Toluene-2,6-diisocyanate April 8, 1981 1982:9 (II)
Trichlorobenzene September 16,1993 1993:37 (XIV)
1,1,1-Trichloroethane March 4, 1981 1982:9 (II)
Trichloroethylene December 14, 1979 1981:21 (I)
Trichlorofluoromethane June 2, 1982 1982:24 (III)
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982:24 (III)
Triethanolamine August 25, 1982 1983:36 (IV)
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Triethylamine December 5, 1984 1985:32 (VI)
Trimellitic anhydride September 12, 1989 1991:8 (XI)
Trimethylolpropane November 16, 1994 1995:19 (XVI)
Trinitrotoluene April 17, 1991 1992:6 (XII)
Vanadium March 15, 1983 1983:36 (IV)
Vinyl acetate June 6, 1989 1989:32 (X)
Vinyl toluene December 12, 1990 1992:6 (XII)
White spirit December 16, 1986 1987:39 (VIII)
Wood dust June 17, 1981 1982:9 (II)
Xylene February 29, 1980 1981:21 (I)
Zinc April 21, 1982 1982:24 (III)
Zinc dimethyl dithiocarbamate September 12, 1989 1991:8 (XI)
Ziram September 12, 1989 1991:8 (XI)
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